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ABSTRACT  
Methylglyoxal (MG) is a highly reactive metabolite produced in the cells. 
Insulin-insensitive vascular cells are the major sites for endogenous MG formation. Elevated 
levels of MG in vascular tissues were reported in metabolic syndrome with hyperglycemia 
(such as type 2 diabetes) or without hyperglycemia (such as hypertension), but the underlying 
mechanism is largely unknown. We observed that in cultured vascular smooth muscle cells 
(VSMCs), fructose (25 mM) treatment up-regulated gene expression of aldolase B and 
enhanced MG formation. Glucose (25 mM) treatment of VSMCs activated the polyol 
pathway and increased fructose formation, leading to aldolase B up-regulation and MG 
overproduction. In our tested rat models with obesity, hypertension or diabetes, serum and 
aortic MG and fructose levels were increased, and the expression of aldolase B in the aorta 
was up-regulated. Our study indicates that aldolase B up-regulation by elevated fructose is a 
common mechanism for vascular MG overproduction in the metabolic syndrome.  
Increased MG accumulation is considered an important molecular mechanism for 
endothelial cell damage in diabetes. Whether knockdown of aldolase B prevents high 
glucose-induced MG overproduction and cellular dysfunction was investigated in the cultured 
endothelial cells. High glucose (25 mM) incubation increased aldolase B mRNA expression 
and MG formation in endothelial EA. hy926 cells. We found that siRNA knockdown of 
aldolase B prevented high glucose-elevated MG levels and the activation of multiple 
metabolic and signaling pathways (i.e. increase in advanced glycation endproducts 
accumulation, oxidative stress, O-linked N-acetyl glucosamine modification of proteins, 
membrane protein kinase C activity and nuclear translocation of nuclear factor κB). Our 
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study further suggests that aldolase B is likely a key target for prevention of MG 
overproduction and related cellular dysfunction not only in VSMCs but also in vascular 
endothelial cells in diabetes and its vascular complications.  
Recently, MG formation in insulin-sensitive cells has received much attention since 
high levels of MG have been found to disturb insulin signaling in 3T3-L1 adipocytes and 
skeletal muscle L6 cells. We, therefore, investigated the mechanisms for MG formation in 
insulin-sensitive 3T3-L1 adipocytes under physiological and pathological conditions. We 
found that insulin (100 nM), glucose (25 mM), or their combination has no effect on cellular 
levels of sorbitol and fructose, in comparison with the control group (5 mM glucose alone). 
Insulin, glucose (25 mM), or their combination decreased aldolase B mRNA to a similar level. 
Glucose (25 mM) had no effect on aldolase A gene expression, but insulin (100 nM) 
markedly increased aldolase A mRNA and protein levels in the absence or presence of 25 
mM glucose. Application of insulin (100 nM) increased the levels of basal or glucose (25 
mM)-induced MG and glucose 6-phosphate. Knockdown of aldolase A prevented the 
increased MG levels induced by insulin (100 nM), glucose (25 mM), or their combination. 
Our data suggest that aldolase A and glycolysis are responsible for the basal and excess MG 
generation in insulin-sensitive adipose cells, especially under the stimulus of insulin.  
In summary, all experiments taken together, show for the first time, that aldolase B is 
responsible for vascular MG overproduction and aldolase A is responsible for adipose MG 
overproduction in metabolic syndrome. Increased MG levels in these cells may contribute to 
endothelial dysfunction, pathogenesis of hypertension and hypertriglyceridemia that 
characterize the metabolic syndrome.   
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1.1 What is methylglyoxal (MG)?  
Methylglyoxal (MG), an α-dicarbonyl compound (Figure 1-1), is also called 
2-oxopropanal, pyruvaldehyde, pyruvic aldehyde or 2-ketopropionaldehyde. MG is present 
mostly in the mono and dihydrate forms [MG-H2O, 71% and MG-(H2O)2, 28%], in aqueous 
solution (1). MG can react with and modify cellular macromolecules, including DNA, 
proteins, peptides, and lipids. In the body, 99% of MG is bound to biomolecules whereas only 
1% is in the free form (2). The high reactivity of MG is due to the electrophilic carbonyl 
group and to the O-atoms which increase the positive charge on the carbonyl carbon (3). 
Therefore, MG displays higher reactivity in nucleophilic addition reactions than other 
dicarbonyl compounds, such as glyoxal and 3-deoxyglucosone (3-DG) (4).   
 
Figure 1-1 Chemical structure and characteristics of methylglyoxal. 
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1.2 Where does MG come and go?  
1.2.1 Sources of endogenous MG 
1.2.1.1 MG formation 
In living organisms, MG is produced through several metabolic pathways (Figure 1-2). 
The primary sources for endogenous MG generation are triosephosphates, glyceraldehyde 
3-phosphate (GA3P) and dihydroxyacetone phosphate (DHAP) (5, 6). GA3P and DHAP are 
produced during glucose or fructose metabolism in cells. Through glycolysis, glucose is 
phosphorylated into glucose 6-phosphate (G-6-P) and further metabolized enzymatically into 
fructose 1,6-bisphosphate (F-1,6-P2), which is cleaved by aldolase A to generate GA3P and 
DHAP (7). Fructose, either derived from the diet (e.g., table sugar and high fructose corn 
syrup) or produced from glucose through the polyol pathway (also known as aldose reductase 
pathway) by the enzymes aldose reductase and sorbitol dehydrogenase, is quickly 
phosphorylated by fructokinase to fructose 1-phosphate (F-1-P) and subsequently split by 
aldolase B into glyceraldehyde and DHAP (7). Glyceraldehyde is phosphorylated by triose 
kinase to form GA3P. DHAP and GA3P can be readily inter-converted by triosephosphate 
isomerase. Both GA3P and DHAP can spontaneously and non-enzymatically degrade to MG 
(5, 6). In addition, DHAP can be also metabolized to MG with the action of MG synthase 
which is found in many microorganisms, such as Escherichia coli and yeast (8, 9).  
Other important sources for endogenous MG generation include ketone bodies 
(mainly acetone) derived from fatty acid oxidation and aminoacetone derived from protein 
catabolism (10). Cytochrome P450 2E1 (CYP 2E1) enzymes catalyze a two-step conversion 
of acetone into MG via acetol as an intermediate (11). Two other ketone bodies acetoacetic 
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acid and β-hydroxybutyric acid can spontaneously convert to acetone and may also be the 
sources for MG formation (12). Semicarbazide-sensitive amine oxidase (SSAO) catalyzes 
MG production via deamination of aminoacetone generated from catabolism of threonine and 
glycine (13). SSAO is predominantly expressed in adipose cells, vascular smooth muscle 
cells (VSMCs), and endothelial cells (14). SSAO (also known as vascular adhesion protein 1) 
is localized on the outer membrane surface. In addition, SSAO is present in the cell 
cytoplasm and in plasma as soluble SSAO (14). Moreover, SSAO stimulates glucose 
transport into VSMCs and adipocytes via glucose transporter GLUT1 (15) and GLUT4 (16), 
respectively. The insulin-like effect of SSAO may contribute to MG formation from the 
increased glucose uptake and metabolism.   
 
1.2.1.2 MG degradation  
MG is degraded in cells mainly by the glyoxalase system which consists of two 
enzymes glyoxalase I and II (10) (Figure 1-2). The glyoxalase system is present in all 
mammalian cells in the cytosol and in cellular organelles, such as mitochondria (17). MG is 
first converted irreversibly by glyoxalase I to (S)-delta-lactoylglutathione using reduced 
glutathione (GSH) as a cofactor and then to D-lactate by glyoxalase II. A minor pathway for 
MG catabolism is mediated by aldose reductase which converts MG to acetol using 
nicotinamide adenine dinucleotide phosphate (NADPH) as a cofactor (18). Aldose reductase 
is an NADPH-dependent aldo-keto reductase that catalyzes the reduction of a variety of 
aldehydes such as MG. The enzyme activity of aldose reductase on MG metabolism is 
40-fold lower than that of glyoxalase I (19).    
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Figure 1-2 Schematic pathways of cellular methylglyoxal (MG) generation and 
degradation. Triosephosphates glyceraldehyde 3-phosphate (GA3P) and dihydroxacetone 
phosphate (DHAP) which are produced form glucose through glycolysis or the polyol 
pathway or produced during fructose metabolism spontaneously and non-enzymatically 
converts to MG. In addition, acetone from fatty acid oxidation and aminoacetone from 
protein catabolism are metabolized to MG with the actions of cytochrome P450 2E1 (CYP 
2E1) and semicarbazide-sensitive amine oxidase (SSAO), respectively. Cellular MG is 
degraded by glyoxalase I and glyoxalase II into D-lactate or by aldose reductase into acetol.   
 
Abbreviations: CYP 2E1 – cytochrome P450 2E1; DHAP – dihydroxacetone phosphate; 
F-1-P – fructose 1-phosphate; F-1,6-P2 – fructose-1,6-bisphosphate; G-6-P – glucose 
6-phosphate; GA3P – glyceraldehyde 3-phosphate; GSH – glutathione; MG – methylglyoxal; 
NADPH – nicotinamide adenine dinucleotide phosphate; SSAO – semicarbazide-sensitive 
amine oxidase; TIM – triosephosphate isomerase.   
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1.2.2 Sources of exogenous MG  
MG has been reported to be present in rice, wheat and tobacco (20). MG is also 
present in a broad range of commercial foods and beverages, such as bread, coffee, honey, 
wine, and beer (21, 22). MG can be formed during the industrial processing, home cooking 
and long-time storage. For example, roasting process increases MG levels in coffee (23), and 
the heating and prolonged storage (20-120 days) increases MG levels in honey (24). It was 
reported that MG was 0.79 mg/kg in bread, 2.5 mg/kg in toast bread, 38-828 mg/kg in 
manuka honey, 100 mg/kg in instant coffee powder, 0.57 μg/ml in wine and 1.5 μg/ml in 
Bourbon whiskey (21, 22). The MG content in these foods and beverages is not normally 
harmful, but an excess consumption over a long-time may increase the risk of MG-related 
diseases, such as hypertension and dibetes (25, 26). Moreover, the absorption of orally 
ingested MG is probably limited.    
Carbohydrates in foods and beverages are susceptible to non-enzymatic degradation 
(mainly through Caramelization and Maillard reaction) during food heat treatment, such as 
roasting, baking, broiling, frying, and evaporating, leading to the formation of α-dicarbonyl 
compounds, particularly MG, glyoxal, and 3-DG (Figure 1-3). At the chemical level, 
caramelization involves ring-opening, enolization of reducing sugars (such as D-glucose), 
sugar dehydration and MG formation (23). The caramelization is normally slow, but becomes 
significant at high sugar concentrations or at high temperatures (23). The Maillard reaction 
begins with reversible formation of unstable Schiff’s base via condensation of an amino acid 
with a reducing sugar. The Schiff’s base undergoes a slowly reversible organic transformation 
known as Amadori rearrangement. Both, the Schiff’s base and the Amadori product 
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Figure 1-3 Methylglyoxal (MG) formation through caramelization and Maillard 
reaction. Glucose in foods and beverages non-enzymatically degrades to α-dicarbonyl 
compounds, such as MG, glyoxal and 3-deoxyglucosone (3-DG), through caramelization 
and/or Maillard reaction during food heat treatment, such as roasting, baking, broiling, frying, 
and evaporating. 
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subsequently degrade into eneaminol and different α-dicarbonyl compounds (27, 28).  
Decomposition of lipids caused by storage and processing may also increase MG 
accumulation in foods. For example, the accelerated storage conditions (60°C for 3 and 7 d) 
and a cooking condition (200°C for 1 h) enhance MG formation in our dietary oils, such as 
fish and olive oils (29). Photodegradation of lipids, fatty acids and related compounds also 
yielded MG. Upon ultraviolet irradiation for 10 h, MG amount was increased in squalene and 
cod liver oils, and to a lesser extent, in ethyl esters of fatty acids, acetaldehyde, acrolein, and 
propanal (30).  
In addition, the use of microorganisms in fermentation can also increase MG 
formation. MG synthase catalyzes the conversation of DHAP to MG and inorganic phosphate 
in many microorganisms, such as Escherichia coli and yeast (8, 9). The release of MG by 
different microorganisms during fermentation may cause an increase of MG in alcoholic 
drinks and dairy products.  
 
1.2.3 Cell permeability of MG  
Incubation of cells with MG leads to cellular MG accumulation dependent on 
extracellular MG concentration, incubation time, and cell types. For example, after 
incubation of L6 skeletal muscle cells with [2-
14
C] MG (2.5 mM, 30 min), 3% of exogenous 
MG was incorporated into the cells, in which about 33% partitioned into the cytosolic 
fraction and 64% was incorporated into the cell membrane fraction (31). Incubation of rat 
aortic smooth muscle cells with [2-
14C] MG (160 μM, 15 min), showed that 1.8% of MG was 
incorporated into the cells (32). Incubation of pancreatic beta cell line INS-1E with [2-
14
C] 
9 
 
MG (0.25-1 mM, 30 min), resulted in 12.5% of MG being incorporated into the cells (33). 
MG can also release into the surrounding environment from cells with increased intracellular 
MG levels. About 10% of endogenously produced MG was released into the culture medium 
from Chinese hamster ovary cells after incubation with 100 mM glucose-containing medium 
for 12 h (34). MG may be able to cross cell membranes but the mechanism of MG transport 
is not known, and it seems dependent on aquaglyceroporin, a subclass of aquaporin water 
channels (35). Extracellular MG was not transported into wild-type Xenopus oocytes, but 
significantly transported into aquaglyceroporin-expressing Xenopus oocytes (35).  
 
1.3 Effects of MG 
1.3.1 MG and advanced glycation endproducts (AGEs) 
MG initially reversibly reacts with certain proteins at arginine, lysine, or cysteine 
residues, and the subsequent irreversible reaction yields AGEs which cause the structural and 
functional changes of proteins. MG is believed to be the major source of AGEs (36) (Figure 
1-4). The formation of AGEs is a spontaneous process. Experiments in test tubes showed that 
incubating purified human insulin with MG (10 µM, 24-72 h) in vitro in phosphate buffered 
saline (PBS, pH 7.4) at 37°C leads to a MG modification of insulin at the arginine residue of 
the beta chain (37), and incubating purified Akt1 with MG (50 µM, 24 h) in vitro leads to a 
MG modification of Akt1 at cysteine 77 (38). 
Irreversible formation of AGEs on proteins would change their structures, disturbing 
their physicochemical and biochemical properties as well as their stability. For example, the 
formation of AGEs on the extracellular matrix molecules, such as fibronectin, laminin, type I  
10 
 
 
Figure 1-4 Chemical structures of advanced glycation endproducts (AGEs). MG reacts 
with arginine residue of proteins to form nonfluorescent products 
5-hydro-5-methylimidazolone (MG-H1) and the major fluorescent product argpyrimidine 
(39). Upon reaction with lysine residue of proteins, it forms N(ε)-carboxyethyl-lysine (CEL), 
N(ε)-carboxymethyl-lysine (CML), and methylglyoxal-derived lysine dimer (MOLD) (40). 
MG also reacts with cysteine residue of proteins to generate carboxyethyl cysteine (CEC) 
(41).   
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and type IV collagens, caused aberrant cross-linking, impaired matrix-matrix interactions, 
and increased the stiffness of the vasculature (42). AGEs formation on extracellular matrix 
also interferes with matrix-cell interactions. Laminin and collagens are basement membrane 
components of blood vessels and play key roles in regulating endothelial cell-cell adhesion 
(43). AGE modification of the cell-binding domains of laminin, type I and type IV collagens 
decreased endothelial cell adhesion and promoted its migration which is important for 
angiogenesis or large vessel repair (44). Arginine, lysine, and cysteine residues are usually 
involved in active sites of enzymes and AGE formation on these residues may impair 
enzymes’ activities. It was reported that the MG-induced glycation reduced activities of 
glyceraldehyde-3-phosphate dehydrogenase, glutathione reductase and lactate dehydrogenase 
(45, 46).  
Moreover, AGEs can exert multiple effects on cells via binding and activating RAGE 
(receptor for AGEs) on the cell surface. RAGE is a member of the immunoglobulin 
superfamily present in a wide variety of cell types, such as endothelial cells, VSMCs, and 
mononuclear phagocytes (47, 48). The engagement of RAGE by AGEs leads to perturbation 
of cellular properties, including excess generation of reactive oxygen species (ROS) through 
NADPH oxidase and activation of multiple signaling pathways, such as p21 RAS, p38 
mitogen-activated protein kinases (MAPK), and the GTPases Cdc42 and Rac (42, 49). A key 
target of RAGE signaling pathways is NF-κB. Binding of AGEs to RAGE induces 
translocation of NF-κB to the nucleus and up-regulation of its targeted genes, including 
several growth factors such as vascular endothelial growth factor (VEGF), transforming 
growth factor-beta (TGF-β) and connective tissue growth factor (CTGF), vasoconstrictors 
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such as endothelin, proinflammatory cytokines such as interleukin (IL) and tumor necrosis 
factor-alpha (TNF-α), and cell adhesion molecules such as vascular cell adhesion molecule-1 
(VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) (50, 51). It was reported that 
circulating AGEs bound to RAGE on the endothelium enhanced endothelial permeability, 
stimulated NADPH oxidase and ROS generation, activated NF-κB, and increased vascular 
inflammation (42, 49, 52, 53). 
 
1.3.2 MG and oxidative stress 
Oxidative stress is a result of an imbalance between ROS production and anti-oxidant 
defense. MG is a pro-oxidant (54, 55).  Dr Wu’s group has observed that incubation of 
cultured aortic VSMCs with MG (10-300 µM) significantly increased superoxide anion (O2
.-
) 
production in a concentration- and time-dependent manner (55). MG also increased the 
formation of hydrogen peroxide (H2O2) and peroxynitrite (ONOO
-
), in the same VSMCs (55). 
Moreover, incubation with MG (50–100 µM, 3 h) significantly increased oxidative stress, as 
determined by the formation of oxidized 2',7'-dichlorofluorescein (DCF, a fluorescent product 
from the oxidation of the reduced non-fluorescent 2',7'-dichlorodihydrofluorescein diacetate 
by various forms of ROS, e.g. H2O2, O2
.-
, and ONOO
-
), in mesenteric artery VSMCs from 
Sprague-Dawley (SD) rats (54). Incubation with MG (50–500 µM, 24 h) significantly 
increased oxidized-DCF fluorescence in VSMCs isolated from the aorta of Wistar–Kyoto 
(WKY) rats, and to a higher extent, in VSMCs isolated from the aorta of spontaneously 
hypertensive rats (SHR) (56). The induction of oxidative stress by MG has been also reported 
in other cell types, such as Jurkat T leukemia cells (57) and cultured rat hepatocytes (58).  
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Figure 1-5 Methylglyoxal (MG)-induced reactive oxygen species (ROS) generation. In 
cells, superoxide (O2
.-
) is produced predominantly by mitochondrial respiration and the 
enzyme NADPH oxidase. O2
.-
 reacts rapidly with nitric oxide (NO), producing peroxynitrite 
(ONOO
-
). MG inhibits mitochondrial complex III activities and increases mitochondrial 
superoxide generation. MG also increases the activities of NADPH oxidases and inducible 
nitric oxide synthase (iNOS), leading to excess generation of O2
.-
, NO and ONOO
-
. 
Superoxide dismutase (SOD) catalyzes the dismutation of O2
.-
 into hydrogen peroxide (H2O2) 
and oxygen. H2O2 can react with Fe
2+
 to form hydroxyl radicals (HO
•
) via Fenton reaction 
(Fe
2+
 + H2O2 → Fe
3+
 + HO
•
 + OH
−
). H2O2 is broken down into water and oxygen by 
catalase (CAT) or by glutathione peroxidase (GPx) with cofactor reduced glutathione (GSH). 
MG decreases the activities of SOD, CAT as well as GPx and enhances the accumulation of 
ROS. Moreover, MG can decrease activities of glutathione reductase (GR) which reduces 
glutathione disulfide (GSSG) to GSH, leading to a reduction in cellular GSH levels.       
Abbreviations: NADPH – nicotinamide adenine dinucleotide phosphate; iNOS and eNOS – 
inducible or endothelial nitric oxide synthase, respectively;  
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Numerous in vitro and in vivo studies have shown that MG stimulates ROS generation 
by impairing mitochondrial function, activating NADPH oxidases and inducible nitric oxide 
synthase (iNOS), and inhibiting activities of antioxidant enzymes and reducing cellular 
antioxidants, such as GSH (59) (Figure 1-5).   
Mitochondria are the powerhouse of mammalian cells, and also the major sites for the 
cellular generation of ROS. During mitochondrial respiration, electrons from donors pass 
through the complexes I – IV of respiration chain (also known as the electron transport chain, 
ETC). Under physiological conditions, 2-5% of electrons leak out to molecular oxygen and 
produce 85% of total intracellular superoxide (60, 61). Increasing evidence suggests that 
mitochondria are important targets of MG. For example, a 5 min incubation with MG 
(10–200 μM) induced a concentration-dependent reduction in the respiration rate of isolated 
rat renal mitochondria (62). Electron leakage in the ETC mainly occurs at complex I 
(NADH-ubiquinone oxidoreductase) and complex III (ubiquinol-cytochrome c reductase) (63, 
64). Inhibition of complex I or III leads to a significant increase in mitochondrial superoxide 
generation (65). Our recent work found that MG specifically inhibited complex III activity 
and increased generation of mitochondrial superoxide (66) (Figure 1-5).  
Another important source for O2
.- 
generation is the NADPH oxidases-catalyzed 
transfer of electrons from NADPH to molecular oxygen (Figure 1-5). NADPH oxidases 
belong to a family of membrane-bound enzymes. In neutrophils, NADPH oxidases are 
transmembrane proteins expressed on the plasma membrane and O2
.- 
is produced outside of 
cells as a defense agent. However, in vascular endothelial cells NADPH oxidases are 
expressed on the plasma membrane and also in the endosomal compartments, and mainly 
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produce O2
.- 
intracellularly (60). For example, the isoform NADPH oxidase 1 is expressed on 
the plasma membrane and NADPH oxidase 4 is expressed in the endoplasmic reticulum of 
endothelial cells (67, 68). By using NADPH oxidase inhibitors, previous work showed that 
NADPH oxidase mediated MG induced-superoxide production in VSMCs and in rat kidney 
mesangial cells (55, 69). More recently, our lab found that incubation with MG (30 µM, 24 h) 
directly increased NADPH oxidase activity and ROS production in human umbilical vein 
endothelial cells and in rat aortic endothelial cells (70).  
MG causes increased nitric oxide (NO) and ONOO
-
 production through its actions on 
iNOS (Figure 1-5). In cells, NO is produced from the oxidation of L-arginine catalyzed by 
constitutive NOS isoforms, such as neuronal NOS (nNOS) and endothelial NOS (eNOS), or 
by iNOS (71). eNOS is primarily expressed in endothelial cells while iNOS is primarily 
expressed in macrophages, VSMCs and other cell types (71). Dr Wu’s group previously 
found that iNOS expression and NO production were increased in the aorta of 14-week old 
SHR as compared to WKY rats, which was associated with elevated aortic and plasma MG 
levels in SHR. However, in the same SHR, aortic eNOS expression was reduced (72). More 
recent work showed that MG (30 µM, 24 h) decreased eNOS activity and decreased basal and 
bradykinin (10 µM)-stimulated NO production in endothelial cells (70). Furthermore, MG 
(10 µM, 6 h) up-regulated iNOS expression and enhanced NO production and ONOO
– 
formation in VSMCs (73). These studies indicate that the effects of MG on NOS and NO 
production vary in different cell types, but the NO bioavailability in both endothelial cells 
and VSMCs is reduced by MG either via reducing NO production or via increasing the 
formation of ONOO
-
, respectively. In addition, mitochondrial NOS (mtNOS) may contribute 
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to MG-induced NO production in VSMCs, as MG (30 µM, 18 h)-increased NO production in 
A-10 cells was inhibited by the addition of the mtNOS inhibitor 7-nitroindazole (66).  
MG can further augment intracellular oxidative stress via inactivating different 
antioxidant enzymes and reducing cellular antioxidants (Figure 1-5). The superoxide 
produced in cells is dismutated by copper-zinc superoxide dismutase (CuZn SOD) or 
mitochondrial superoxide dismutase (Mn SOD) to H2O2 (60), which is further decomposed to 
water and oxygen by catalase or glutathione peroxidase (GPx) (74). MG has been found to 
inactivate SOD, catalase, and GPx. After incubation with MG in test tubes, the activities of 
the purified CuZn SOD and GPx were inhibited (75, 76). When VSMCs were treated with 
MG, activities of Mn SOD and GPx were significantly decreased (66). Incubation of mice 
liver homogenate with MG (0.1-10 mM) inhibited activities of SOD and catalase (77). 
Moreover, animal studies showed that Swiss albino male mice which were administered MG 
(50-400 mg/kg body wt, i.p.) had lower SOD and catalase activities in the liver than control 
mice (77). GSH is an important antioxidant in the cells and plasma. GSH effectively 
scavenges various ROS including H2O2, ONOO
-
, and hydroxyl radical, through direct 
interactions or indirect enzyme-catalyzed reactions (78). In these processes, GSH is oxidized 
to form glutathione disulfide (GSSG). Glutathione reductase (GR) recycles GSSG to GSH 
(78). Chronic MG infusion (60 mg/kg/day) by minipump significantly reduced GSH levels in 
the plasma, pancreas, and skeletal muscle in SD rats (26). MG can directly inactivate GR in 
test tubes (79). Cell studies demonstrated that incubation of MG significantly decreased GR 
protein expression and reduced GSH levels in VSMCs and endothelial cells (56, 70).  
MG increases oxidative stress partially through the formation of AGEs. Previous 
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studies observed that the formation of AGEs in the mitochondria increased mitochondrial 
ROS generation (80, 81). AGEs also impaired functions of antioxidant enzymes, such as 
CuZn SOD and GPx (75, 76), Moreover, binding of AGEs to RAGEs activates NADPH 
oxidases and promotes the generation of ROS (82). Our recent work showed that the AGEs 
breaker alagebrium completely decreased AGE formation but only partially reduced 
MG-increased mitochondrial superoxide generation and intracellular nitrotyrosine, products 
of tyrosine nitration in proteins mediated by peroxynitrite, in VSMCs (66). These studies 
indicate that MG modification of proteins or AGEs formation may in part contribute to 
MG-induced oxidative stress.    
 
1.4 Increased MG accumulation in metabolic syndrome  
Metabolic syndrome is a cluster of metabolic abnormalities associated with obesity, 
type 2 diabetes, and hypertension, including abdominal obesity, hyperglycemia, glucose 
intolerance, insulin resistance, dyslipidaemia, and high blood pressure (83). Over the past two 
decades, the number of people with metabolic syndrome has strikingly increased, and it has 
become one of the major public-health challenges worldwide (83). A large and growing 
number of studies suggest that MG is an important cause for the development of diabetes and 
hypertension, although its role in obesity has not yet been established.  
 
1.4.1 MG, diabetes and its vascular complications 
1.4.1.1 Increased MG accumulation and MG-induced AGEs in diabetes 
Plasma MG levels in healthy human subjects are 1-3 µM (72, 84) and in rats the 
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normal levels are approximately 1 μM (26, 85). In patients with type 2 diabetes, plasma MG 
levels are two to four-fold elevated (86). This increase is positively correlated with levels of 
fasting plasma glucose, glycosylated hemoglobin, and the ratio of urine albumin to creatinine 
(86). Increased AGEs formation in the blood and tissues occurs with aging and is exaggerated 
by hyperglycemia in diabetes (86). The MG levels were increased in the kidney and retina, 
the major sites of diabetic microvascular complications, but not in the liver and skeletal 
muscles in streptozotocin (STZ)-induced diabetic rats (87). Immunohistochemical analyses 
showed that in diabetic rats or mice, AGE levels are increased in the aorta (88), mesenteric 
vessels (89) and retinal vessels (90). Diabetes-associated accumulation of AGEs in blood 
vessels is linked to the development of diabetic vascular complications. In patients with type 
I diabetes, levels of AGEs in the kidney and the retina were associated with the degree of 
nephropathy and retinopathy, respectively (91). For example, in these patients with type 1 
diabetes, AGE levels were significantly elevated in the kidney as urinary albumin increased 
during the early phase of nephropathy (91). In diabetic rats, increased renal AGE levels were 
associated with the morphological abnormalities of diabetic nephropathy, such as glomerular 
basement membrane thickening (92), and of diabetic retinopathy, such as abnormal 
endothelial cell proliferation (93). Moreover, in the STZ-induced diabetic apolipoprotein 
E-deficient (apoE-/-) mouse (a model of diabetes-associated atherosclerosis), levels of AGEs 
in the plasma and the aorta were elevated and associated with an increase of atherosclerotic 
plaque area (88). In addition, clinical studies in patients with type 2 diabetes showed that the 
increased levels of blood MG or AGEs were correlated with decreased endothelium- 
dependent vasodilation (94) and the degree of intima-media thickness of blood vessels, 
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vascular stiffness, and systolic blood pressure (95). These data suggest that increased 
generation of MG is a cause for the vascular complications of diabetics (95).   
 
1.4.1.2 MG and other molecular mechanisms for hyperglycemic damage  
1.4.1.2a MG, glucose and oxidative stress 
High glucose increases superoxide generation from mitochondrial respiratory chain 
and NADPH oxidases and reduces the activity of SOD and levels of antioxidants such as 
GSH and vitamin E in VSMCs and endothelial cells (96-98). Superoxide can be converted to 
hydroxyl radical and H2O2 (Figure 1-5). Oxidative stress due to increased ROS generation 
leads to oxidation of biological macromolecules such as DNA, lipids, and proteins. Moreover, 
high glucose also stimulates the expression of iNOS and promotes the formation of NO 
which reacts with superoxide to produce the highly reactive ONOO
-
 (99). ONOO
-
 can react 
with amino acids such as tyrosine to form nitrotyrosine (100). In addition, the reaction of NO 
and superoxide during hyperglycemia reduces NO availability and impairs 
endothelium-dependent vasodilation (101). Furthermore, excess ROS activates different 
signaling pathways and alters gene expression (102). For example, in VSMCs, cytosolic ROS 
such as H2O2 and superoxide activated p38 MAPK and ERK 1/2 signaling pathways and 
mitochondrial ROS activated the JAK/STAT signaling pathway, causing cell proliferation, 
protein synthesis and hypertrophy (103). In vascular endothelial cells, 
hyperglycemia-induced generation of ROS activated the JNK/SAPK pathway, causing cell 
apoptosis (104), while activation of activator protein-1 (AP-1) caused a decrease in eNOS 
expression (105). As mentioned earlier, MG can enhance the formation of superoxide, NO 
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and peroxynitrite in VSMCs and endothelial cells, however, whether MG is the key mediator 
for high glucose-induced ROS is largely unsettled.    
 
1.4.1.2b MG and activation of the hexosamine pathway 
Through the hexosamine pathway, the glycolytic metabolite fructose-6 phosphate is 
first converted to glucosamine-6 phosphate and then to uridine diphosphate N-acetyl 
glucosamine (UDP-GlcNAc), catalyzed by fructose 6-phosphate amidotransferase (GFAT). 
O-linked N-acetyl glucosamine (O-GlcNAc) modification or O-GlcNAcylation is a process in 
which in the presence of O-GlcNAc transferase (OGT), the GlcNAc from UDP-GlcNAc is 
transferred to the serine and threonine residues of various nuclear and cytosolic proteins 
(106). With O-GlcNAc modification proteins will lose their normal function.  
Hyperglycemia-increased flux through the hexosamine pathway has been implicated in the 
pathogenesis of diabetic complications (106). For example, high glucose enhanced 
UDP-GlcNAc formation and increased O-GlcNAc modification of nuclear transcription 
factors, such as Sp1, leading to up-regulated gene expression of plasminogen activator 
inhibitor-1 (PAI-1) and transforming growth factor-beta 1 (TGF-β1) in aortic endothelial cells 
(107). The high glucose-increased O-GlcNAc modification of eNOS in aortic endothelial 
cells leads to a significant reduction in eNOS activity (108). Inhibition of 
glutamine:fructose-6-phosphate amidotransferase (GFAT) in porcine glomerular mesangial 
cells prevented high glucose-increased formation of glucosamine metabolites (glucosamine-6 
phosphate and UDP-GlcNAc) and inhibited TGF-β1 gene expression, bioactivity and its 
effects on cell proliferation and matrix production (109).  
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There is some indirect evidence that implicates MG in the high glucose-activated 
hexosamine pathway. For example, O-GlcNAc modification of the proteasome was increased 
in the kidney of glyoxalase-1 knockout mice (110), and over-expression of glyoxalase-1 in 
endothelial cells reduced high glucose-induced O-GlcNAc modification of transcription 
factor Sp3 (111). However, whether MG increases O-GlcNAc modification remains to be 
clarified.  
 
1.4.1.2c MG, AGEs and activation of protein kinase C (PKC) isoforms 
PKC is a family of protein kinase enzymes that phosphorylate serine and threonine 
residues of intracellular proteins and play important roles in a variety of cellular functions 
such as signal transduction (112). PKC is activated by signals such as diacylglycerol (DAG) 
and calcium or by ROS such as H2O2 (113). Upon activation, PKC is translocated into the 
plasma membrane where PKC catalyzes phosphorylation of various substrates and mediates a 
diverse variety of biological processes (114).  
The PKC activities were increased after incubation with high glucose in VSMCs and 
endothelial cells (115). In the endothelial cells, PKC activation affects the production of 
endothelium-dependent vasodilators and vasoconstrictors (i.e. deceasing NO and prostacyclin 
but increasing thromboxane and endothelin-1) and increases cell permeability and 
angiogenesis via the expression of vascular endothelial growth factor (113). In VSMCs, PKC 
activation alters the smooth muscle contractility and hormone responsiveness (116) and 
promotes cell migration and proliferation (117). PKC activation also contributes to high 
glucose-induced activation of NADPH oxidases and generation of ROS in VSMCs and 
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endothelial cells (112). Moreover, activation of PKC was found to up-regulate gene 
expression of TGF-β1, fibronectin and collagen, and to increase accumulation of 
microvascular matrix proteins in glomeruli of diabetic rats (118). Clinical trials have shown 
the benefits of PKC inhibitors in the therapy of diabetic vascular complications. For example, 
pre-treatment with the PKC-β inhibitor LY333531 prevented the reduction in 
endothelium-dependent vasodilation induced by hyperglycemic clamp in healthy people (119), 
and treatment with ruboxistaurin, an orally administered PKC-β inhibitor, decreased the 
vision loss in patients with diabetic retinopathy (120). 
MG seems to activate PKC through the formation of AGEs. PKC can be activated by 
AGEs directly (121) or indirectly through activation of AGEs receptors or generation of ROS 
(122). Inhibition of AGEs decreased the high glucose-increased PKC expression and 
activation in cultured VSMCs and in the kidney of STZ-diabetic rats (123).     
 
1.4.1.2d Activation of nuclear factor κB (NF-κB) 
NF-κB is present in the cytosol as an inactive heterodimeric complex, consisting of 
the p50 and p65 subunits associated with an inhibitory protein κB (IκB), in the resting cells. 
Divergent stimuli such as hyperglycemia, ROS, proinflammatory cytokines, AGEs, and PKC 
activate NF-κB through a common mechanism, IκB kinase-mediated phosphorylation and 
subsequently proteasome-mediated degradation of IκB (42, 97, 124, 125). Activated NF-κB 
(p50/p65 dimer) is translocated to the nucleus and regulates the expression of a large number 
of genes involved in the immune and inflammatory response, apoptosis, cell proliferation and 
differentiation, such as growth factors (i.e. VEGF), proinflammatory cytokines (i.e. TNF-α 
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and IL-1β), RAGE and adhesion molecules (i.e. vascular cell adhesion molecule-1) (125). 
Activation of NF-κB by high glucose has been observed in VSMCs and endothelial cells and 
in different vascular tissues of diabetic rats, and implicated in the pathogenesis of diabetes 
and its associated complications (126-128).  
MG is a stimulus for NF-κB activation. Previous studies with cultured VSMCs and 
retinal capillary pericytes demonstrated that MG treatment directly activated NF-κB (56, 129). 
Moreover, incubation with AGEs induced NF-κB activation in cultured endothelial cells 
(130). As mentioned earlier, AGEs bound to RAGE induce translocation of NF-κB into the 
nucleus and NF-κB–mediated gene expression.   
 
1.4.2 MG and hypertension  
1.4.2.1 Increased MG accumulation and MG-induced AGEs in hypertension   
Plasma MG levels are elevated in hypertension without hyperglycemia. Wang et al. 
found that in 20-week-old SHR, plasma MG levels were two-times higher than those in 
age-matched control non-hypertensive WKY rats (131). Increased MG and MG-induced 
AGEs in plasma and/or the aorta correlated with the development of hypertension in SHR 
(131, 132). As SHR developed hypertension, MG levels in the aorta increased in an 
age-dependent fashion, although there was no difference in blood glucose levels between the 
SHR and WKY rats (131). In the same SHR, AGEs formation, such as CEL and CML, was 
also elevated in the aorta and the mesenteric arteries when compared with WKY rats (72, 
131). Along with the elevated levels of MG and AGEs in VSMCs, in the aorta and kidney of 
13-week-old SHR, ROS generation was increased and levels of GSH and activities of GR and 
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GPx were lowered in these cells or tissues when compared with WKY rats (56, 72, 131, 132). 
However, the mechanisms for vascular MG overproduction or accumulation are unknown.  
 
1.4.2.2 MG-induced vascular remodeling in hypertension 
Vascular remodeling includes the changes in wall thickness, lumen diameter, 
cross-sectional area, and media-to-lumen ratio of blood vessels. There are three types of 
vascular remodeling. Hypertrophic remodeling refers to the increase of cross-sectional area, 
eutrophic remodeling refers to no change of cross-sectional area, and hypotrophic remodeling 
refers to a decrease of cross-sectional area. These forms of remodeling can be inward and 
outward, representing the decrease and increase of lumen diameter, respectively. Current 
evidence suggests that MG can induce hypertrophic inward remodeling of the vasculature 
(aorta and mesenteric artery) (73). This vascular remodeling is associated with increased 
levels of MG and MG-induced AGEs in the aorta and mesenteric arteries of 13-week-old 
SHR (72). Similarly, increased MG and AGEs with mesenteric artery vascular remodeling 
and hypertension were also observed in SD rats after chronic feeding with the MG precursor 
fructose for 16 weeks (25). A clinical study on hypertensive human subjects showed that the 
increase in plasma AGEs was related to the increase of aortic stiffness (133). A recent study 
in our lab on VSMCs (A-10 cell line) found that MG treatment increased DNA synthesis and 
cell proliferation by modifying Akt1 at Cys77 and activating Akt1 signaling pathways (38). 
MG treatment of SD rats through chronic infusion with an implanted minipump for 4 weeks 
augmented phospho-Akt1 (the active form of Akt1) levels in the aorta (38).  
Moreover, MG treatment increases the expression of growth factors, such as TGF-β1 
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and CTGF, and expression of extracellular matrices, leading to progressive thickening of 
blood vessels (50, 51, 134). In Wistar rats treated with MG (i.p., 50-75 mg/kg per day, 7 
weeks), the pro-matrix expansion growth factor CTGF was over-expressed, and luminal 
matrix contents, luminal occlusion and wall thickness were increased in cutaneous arteries 
(134). On the other hand, MG modifies extracellular matrix proteins, leading to inter-protein 
crosslinking and subsequent arterial stiffness (106). For example, oral administration of MG 
(50 mg/kg in drinking water, 5 months) increased total collagen content in the kidney of mice 
but the solubility of these collagens was significantly decreased due to the increase of cross 
linking (135).  
 
1.4.2.3 MG-induced endothelial dysfunction in hypertension 
Endothelial dysfunction is considered a key event in the pathogenesis of hypertension 
and vascular complications of diabetes (136). It is commonly defined as reduced 
endothelium-dependent vascular relaxation, resulting from decreased NOS expression, NO 
bioavailability and NO-mediated muscle relaxation in blood vessels (137). As mentioned 
earlier, NO is produced from L-arginine by the action of eNOS in the endothelium. Different 
stimuli, such as acetylcholine, bradykinin, insulin, VEGF, shear stress and isometric 
contraction, can activate eNOS and promote NO production. For example, eNOS requires 
calcium for its activity and BK can increase intracellular calcium and activates eNOS, while 
insulin can stimulate phosphorylation of eNOS (phospho-eNOS, the active form of eNOS) 
(138, 139). NO generated within the endothelium diffuses to the VSMCs where it activates 
soluble guanylate cyclase, increases generation of cyclic guanosine monophosphate (cGMP) 
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and causes vascular smooth muscle relaxation (139).  
Treatment with MG (0.2% to 0.8% in drinking water, 18 weeks) decreased serum NO 
levels and increased blood pressure (140). When WKY rats were treated with a MG precursor, 
fructose (4% in drinking water), systolic blood pressure was continuously increased during 
1-5 weeks of treatment, and after 11 weeks of treatment, the mean blood pressure in 
fructose-fed rats was significantly higher than that in control rats (141). Our lab found that 
acetylcholine-induced endothelium-dependent relaxations were significantly impaired in 
small mesenteric arteries from 13-week-old SHR in comparison with that from WKY rats 
(72). Treatment of cultured endothelial cells with MG (30 µM, 24 h) reduced basal and 
bradykinin -stimulated NO production, cellular cGMP levels, and eNOS phosphorylation (at 
Ser-1177) and activity (70). Moreover, when the isolated aortic rings from SD rats were 
incubated with MG (30 or 100 µM, 2 h), the acetylcholine-induced endothelium-dependent 
relaxation was inhibited significantly (70). These results are consistent with a recent study 
which showed that incubation of isolated rat mesenteric arteries with MG (0.33 or 1 mM for 
1 h, or 10 or 50 µM for 2 h) resulted in significant impairment of acetylcholine-induced 
vascular relaxation (142). The deleterious effects of MG are attributed to the MG-increased 
oxidative stress, especially superoxide, which reacted with NO and subsequently reduced 
bioavailability of NO in the isolated blood vessels and in cultured endothelial cells (70). The 
MG-impaired endothelium-dependent relaxation in the isolated aorta or mesenteric arteries 
was prevented by application of antioxidants, such as SOD mimetics or N-acetyl-l-cysteine 
(70, 142). More recently, our lab found that MG reacted with H2S, a natural vasodilator, 
which implicates MG in the pathogenesis of hypertension (143).  
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1.5 MG overproduction and possible mechanisms 
1.5.1 MG formation in insulin-insensitive vascular cells and insulin-sensitive adipocytes 
Vascular smooth muscle and endothelial cells are considered major sites for 
endogenous MG production. A study on MG distribution in normal SD rats showed that MG 
formation is highest in the aorta, which is 2-6 fold higher than that in the lung, brain, liver, 
kidney, heart, and spleen (85). A similar result was reported by Randell et al. that MG levels 
in the aorta of normal SD rats are 3-4 times higher than that in the heart, liver and the kidney 
(144). Increased MG formation occurs with the increased availability of its upstream 
metabolites, such as glucose. Most glucose enters insulin-insensitive cells, such as VSMCs 
and endothelial cells, through an insulin-independent glucose transporter 1 (GLUT1) (145). 
High glucose significantly elevated cellular MG levels in VSMCs and in endothelial cells (70, 
146). Increased MG production in vascular tissues has been considered an important 
mechanism for the development of diabetes and diabetic vascular complications (106).  
Recent in vitro studies showed that treatment with MG impaired insulin signaling in 
cultured 3T3-L1 adipocytes (147) or skeletal muscle L6 cells (31). Moreover, MG modified 
insulin molecule and impaired its biological functions, such as its stimulation of glucose 
uptake in adipocytes (37). These observations raise a great interest in MG formation in the 
insulin-sensitive cells. Glucose enters adipose and skeletal muscle cells mainly through an 
insulin-responsive glucose transporter 4 (GLUT4) (145). Insulin can promote membrane 
translocation of GLUT4 and stimulate glucose transport in adipose and skeletal muscle cells 
(148). High levels of insulin can also enhance glycolysis via up-regulating the transcription of 
glycolytic enzymes, such as hexokinase II, phosphofructokinase, and glyceraldehyde 
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3-phosphate dehydrogenase (GAPDH) (149, 150). It is of great significance and interest to 
investigate MG formation in insulin-sensitive cells under the conditions of high insulin.  
 
1.5.2 MG and hyperglycemia  
1.5.2a Aldolase A-glycolysis pathway  
Spontaneous non-enzymatic fragmentation of GA3P and DHAP are considered the 
major sources for endogenous MG generation (5, 6). Most of the glucose is physiologically 
metabolized through glycolysis in which glucose is first phosphorylated to glucose 
6-phosphate by the enzyme hexokinase and further enzymatically converted to fructose 
1,6-bisphosphate (F-1,6-P2) (7). Aldolase A cleaves F-1,6-P2 to generate GA3P and DHAP 
(7). Aldolase A can also split F-1-P into glyceraldehyde (whch is phosphorylated by triose 
kinase to form GA3P) and DHAP, but its activity on the cleavage of F-1-P is 50-fold less 
than the cleavage of fructose F-1,6-P2 (7). Aldolase A is one of three structurally distinct 
forms of aldolases. Two other aldolase isozymes are aldolase B and brain-specific aldolase C 
(7, 151). Aldolase A is an important glycolytic enzyme ubiquitously expressed in many 
tissues, such as skeletal muscle, adipose tissue, liver, kidney, and the intestine (151).  
 
1.5.2b Increased polyol pathway flux during hyperglycemia  
Glucose can be metabolized to fructose through the polyol pathway in which aldose 
reductase reduces glucose to sorbitol, and then sorbitol dehydrogenase oxidizes sorbitol to 
fructose (106). Under physiological conditions, most glucose is metabolized through the 
glycolytic pathway since hexokinase has a much higher affinity for glucose than aldose 
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reductase (152). However, in diabetes with hyperglycemia, glucose can quickly enter VSMCs 
and endothelial cells through insulin-independent GLUT1, and this glucose influx saturates 
hexokinase and activates the polyol pathway. It was reported that aldose reductase was 
up-regulated and up to 30% of the glucose was channeled into the polyol pathway under 
hyperglycemic conditions (153, 154). Fructose is phosphorylated to F-1-P by fructokinase 
and subsequently cleaved to yield glyceraldehyde and DHAP by aldolase B (7). 
Glyceraldehyde is phosphorylated by triose kinase to form GA3P. Gene expression of 
aldolase B was previously detected in the liver, kidney and small intestine (155). Aldolase B 
is the key enzyme responsible for fructose metabolism. Aldolase B has high specific activity 
toward the substrate F-1-P (155). Deficiency of aldolase B due to gene mutations results in 
hereditary fructose intolerance in humans (156, 157).    
 
1.5.3 MG and aldolase B-fructose pathway  
Fructose is a monosaccharide found in fruits, vegetables (including sugar cane), and 
honey. Fructose is also present in sucrose or table sugar that contains equal parts of glucose 
and fructose and in high-fructose corn syrup (HFCS), a synthetically manufactured sweetener 
used in the food industry containing between 55–90% fructose. In the past 30 years, dietary 
fructose consumption has increased markedly due to the increased use of sucrose and HFCS 
(158). Individual consumption of fructose in the western world was only 0.5 lb/year in 1970 
but rose to in 62.4 lb/year by 1997 (159). The excessive intake of fructose is one proposed 
cause of metabolic disturbance including insulin resistance, weight gain, hyperlipidemia, 
hypertension and heart diseases in humans and in animal models (158-161).  
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Using gas chromatography/mass spectrometry (GC/MS), Kawasaki et al. reported that 
the physiological concentration of fructose in serum is about 8.1 ± 1.0 μM in healthy humans 
and about 12.0 ± 3.8 μM in diabetic patients (162). The serum concentration of fructose in 
diabetic patients with ketoacidosis reaches 205 μM and higher (163). It should be noted, 
however, that the reported fructose levels in serum or plasma of healthy humans varies 
widely depending on the analytical method used, and were from µM range measured by 
GC/MS (162, 164, 165) to mM range measured by enzymatic methods (166-169). Using 
enzymatic methods, the concentration of blood fructose is 0.1-0.5 mM under physiological 
conditions, but can increase to 1-2 mM after consumption of fructose or sucrose (166, 170).  
Dietary fructose rapidly diffuses into blood vessels from the intestine through a 
specific fructose transporter, GLUT5, on the intestinal epithelium (171). The main portion of 
absorbed fructose is metabolized in the liver where fructose is converted by highly expressed 
fructokinase and aldolase B to GA3P and DHAP, as illustrated in Figure 1-2. It was reported 
that the liver metabolized about 50% of fructose injected intravenously in humans (172). 
Fructose can up-regulate the gene expression of gluconeogenic enzymes (such as fructose 
1,6-bisphosphatase and glucose 6-phosphatase) and lipogenic enzymes (such as pyruvate 
kinase, fatty acid synthase and glyceraldehyde 3-phosphate acyltransferase) in the liver. The 
major portion of GA3P and DHAP produced from fructose can be subsequently converted 
into glucose, glycogen and lipid (161, 173, 174). The left portion of absorbed fructose 
(approx. 30-45%) is available for extraction and utilization by other tissues expressing 
GLUT5, such as the kidney, adipose tissue and skeletal muscle (175). Whether there is 
expression of GLUT5 and fructose transport in VSMCs and vascular ECs is not known, but 
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our lab previously found that incubation with fructose significantly increased MG formation 
in VSMCs (73, 146).  
Studies from clinical and basic researches have indicated that a diet high in fructose or 
sucrose can induce hypertension, insulin resistance, hyperinsulinemia, and diabetes, although 
the underlying mechanisms are unclear (25, 176-182). Some suggestions have been linked to 
elevated serum uric acid and C-reactive protein expression, endothelial dysfunction, and 
oxidative stress in adipocytes (183, 184). In a human study, the consumption of sucrose at 
152 g/day mostly as beverages for 10 weeks resulted in weight gain and a rise in systolic 
blood pressure (185), while under the same conditions consumption of artificial sweeteners 
with zero sucrose caused no such changes. An increase in diastolic blood pressure was also 
reported in healthy adults after 6 weeks of 33% sucrose diets (177). As in humans, rats fed 
with fructose displayed metabolic syndrome (186) and developed renal hypertrophy, afferent 
arteriolar thickening, glomerular hypertension, and cortical vasoconstriction (182).  
Our lab recently found that the development of vascular remodeling, endothelial 
dysfunction and high blood pressure in fructose-fed SD rats was associated with the high 
fructose-elevated MG levels in serum, aorta and the mesenteric artery (25). Moreover, an 
age-dependent elevation of MG levels in the plasma and the aorta has been observed in SHR 
that had normal blood glucose (131). Whether blood fructose is increased and is responsible 
for aortic MG overproduction in SHR is unknown.  
 
1.5.4 MG and Insulin  
High levels of insulin can increase glucose transport and cellular glucose 
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concentrations in adipocytes under normal glucose conditions (187). Moreover, insulin can 
up-regulate the gene expression of glycolytic enzymes independent of extracellular glucose 
concentrations (149, 150), as mentioned earlier. It is well known that people or experimental 
animals (i.e. rats and mice) with obesity or hypertension have higher blood insulin levels than 
healthy controls, although their blood glucose remains in a normal range (188-191). Studies 
with rat models of obesity showed that adipose cells are normally insulin sensitive at the 
early stage of obesity but become insulin resistant at the late stage (192, 193). However, 
whether high insulin enhances MG formation in insulin-sensitive adipocytes is not known.  
The fructose transport in cells is independent of insulin stimulation, but high levels of 
insulin have been reported to up-regulate GLUT5 gene expression in some cell types, such as 
skeletal muscle cells (194). However, whether GLUT5 is up-regulated by insulin and 
contributes to MG overproduction in VSMCs is not clear. Moreover, little else is known 
about GLUT5 regulation and MG formation in the aorta of rats with hypertension or obesity. 
 
1.6 Strategies to inhibit MG accumulation and MG-induced AGEs   
Currently, no specific and potent scavengers against MG are available although 
N-acetyl-cysteine, guanidine compounds (such as aminoguanidine and metformin), and 
alagebrium have claimed their capability to react with or detoxify MG (195, 196). These 
pharmacological compounds are either non-specific for MG or associated with harmful side 
effects. The clinical trials of aminoguanidine (AG) have proved disappointing due to its 
nonselective inhibition of neuronal, endothelial and inducible NOS (197, 198). Alagebrium is 
thought to be the only AGE crosslink breaker, yet the results of preclinical (199-201) and 
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clinical (202-204) trials remain ambiguous (205) and the AGE-breaking ability of alagebrium 
is not consistently validated (206).   
 
1.6.1 MG scavengers   
Guanidine compounds, such as AG and metformin, are the most widely used MG 
scavengers. However, guanidine compounds are not specific since their guanidine residues 
can interact with the carbonyl in MG or in other carbonyl compounds, such as glyoxal, 3-DG 
and malondialdehyde (MDA) (205).  
 
1.6.1.1 Aminoguanidine (AG)   
AG, also known as pimagedine, directly reacts with MG and thereby prevents the 
related AGEs formation. An in vitro study showed that AG can react with MG in the test tube 
to form 3-amino-5-methyl-1,2,4-triazine and 3-amino-6-methyl- 1,2,4-triazine, which are 
identified by UV spectra and proton nuclear magnetic resonance spectroscopy (207). It has 
been reported that treatment with AG (100 µM) significantly reduced cellular MG levels in 
glucose (25 mM) or MG (30 or 100 µM)-treated endothelial cells (70). Numerous studies 
have shown that AG can prevent or reduce vascular remodeling in diabetic or hypertensive 
rats. Treatment of STZ-diabetic rats with AG (1 g/L in drinking water, 3 weeks or 8 months) 
prevented the diabetes-induced over-expression of TGF-β and collagens as well as increase of 
media-to-lumen ratio in mesenteric vessels without effects on food intake (89). AG treatment 
retarded the AGE modification of aortic collagen and decreased arterial wall protein 
cross-linking and aortic stiffening in diabetic rats (208-210). In SHR treated with AG, the 
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decreased lumen diameter and increased wall thickness and media-to-lumen ratio in the aorta 
and mesenteric arteries were prevented (72). Treatment with AG (0.5-1 g/L in drinking water, 
4 weeks) reduced ventricular hypertrophy and diastolic stiffness constants in DOCA-salt 
hypertensive rats (211).  
However, the benefit of AG on endothelial dysfunction is controversial. AG is also an 
inhibitor of NOS (212). Incubation with AG at 1 mM inhibited activities of iNOS and 
constitutive NOS (212). Chronic administration of AG (15 mg/ kg/day in drinking water, 9 
weeks) reduced the aortic iNOS expression and plasma NO production in SHR (213). Some 
reports showed that AG treatment (25-50 mg/kg/day, s.c., or 250-750 mg/L in drinking water, 
6 weeks) did not prevent the decrease in vasodilatory responses to acetylcholine in skeletal 
muscle arterioles, aorta and the mesenteric arteries of STZ-diabetic rats (214-216). Other 
reports indicated that pre-treatment with AG (250 mg/kg/day by oral gavage, 7 d before the 
induction of diabetes) partially prevented the time-dependent progression of impaired aortic 
vasodilatation to acetylcholine in STZ-diabetic rats (217), and 3-month treatment with AG 
(50 mg/kg/day in the drinking water) restored eNOS expression and partially improved the 
cetylcholine-induced vascular relaxation of mesenteric arteries in type 2 diabetic mice (218). 
Treatment with AG (1 g/L in drinking water, 9 weeks) restored acetylcholine-induced 
vascular relaxation in mesenteric arteries, increased eNOS expression and reduced iNOS 
expression in the aorta, and partially attenuated the increase in blood pressure in SHR (72).  
Aminoguanidine also irreversibly inhibits SSAO, an enzyme which catalyzes the 
conversion of aminoacetone to MG, as mentioned earlier (219). When the SSAO isolated 
from the rat aorta and human umbilical artery was incubated with AG at a concentration of 10 
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µM or 1 mM for 30 min, SSAO activity was reduced by 20% or totally inhibited (219). An in 
vivo study showed that Wistar rats after treatment with AG (10 mg/kg i.p., 3 h) reduced their 
aortic SSAO activity by > 90% (219). However, SSAO is still considered a minor contributor 
for MG formation. Moreover, AG can react directly with ROS, such as H2O2, hydroxyl 
radical and ONOO
-
 (220). In vitro, AG reduced H2O2, hydroxyl radical, and ONOO
-
 levels at 
a concentration of 10, 1 and 0.1 µM, respectively (220).  
 
1.6.1.2 Metformin  
Metformin is an oral hypoglycemic agent for the treatment of type 2 diabetes. 
Metformin has been found to react with MG directly to form stable triazepinone derivatives 
in the test tube and in plasma samples of type 2 diabetic patients (221, 222). However, a high 
dose of metformin is required to achieve its MG and AGEs lowering effect (196, 198). 
Treatment with high-dosage metformin (1-2.5 g/day orally, 3 months) significantly lowered 
plasma MG levels in patients with type 2 diabetes, but the lower dosage of metformin (0.5-1 
g/day, 3 months) had no effect (196). Chronic treatment with metformin both at low dose 
(50-65 mg/kg/day, 10 weeks) and high dose (500-650 mg/kg/day, 10 weeks) reduces AGEs 
formation in the lens, kidney and nerves in diabetic rats (223). Fructose-elevated MG and 
AGEs levels were significantly decreased when rats were co-fed with metformin (500 
mg/kg/day in drinking water, 9 weeks) (25).    
Metformin is also a non-specific MG scavenger. It can react with other reactive 
α-dicarbonyl compounds, such as glyoxal (221), and with ROS, such as superoxide anion and 
hydroxyl radical (224).  
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1.6.2 AGEs breakers  
Alagebrium (also known as ALT-711) breaks the established AGE crosslinks (205). 
Alagebrium is a stable derivative of phenacylthiazolium bromide (PTB), the first AGE 
breaking compound reported in 1996 (205). Since PTB degrades rapidly, alagebrium, which 
is more stable, was developed. Previous studies with VSMCs showed that MG (30 
μM)-increased AGEs levels were completely decreased by treatment with alagebrium (50 or 
100 μM) (66). In STZ-diabetic rats, treatment with alagebrium after 1 week of STZ injection 
resulted in a significant reduction in diabetes-increased levels of AGEs in the serum, aorta 
and the kidney (88, 225). Administration of alagebrium in 3-, 7- or 12-month-old diabetic 
db/db mice for 12 weeks decreased diabetes-elevated CML levels in the serum, skin, and 
kidney, and increased urinary CML excretion (226). These studies suggest that alagebrium 
breaks the preexisting AGEs in vitro and in vivo. 
The administration of alagebrium (1.0 mg/kg/day i.p, 1-3 weeks) in STZ-diabetic rats 
reduced collagen crosslinks, and reversed systemic arterial stiffness (201). In the 
STZ-diabetic rats or diabetic db/db mice, treatment with alagebrium restored 
diabetes-decreased collagen solubility and attenuated diabetes-increased renal collagen 
content and growth factor expression (123, 225, 226). Moreover, alagebrium has been found 
to improve endothelial dysfunction. Treatment with alagebrium (1 mg/kg i.p., 2 weeks) 
restored diabetes-decreased endothelium-dependent vasodilation in diabetic mice (227). 
When 60-week-old SHR were treated with alagebrium (oral gavage, 1 mg/kg/day, 8 weeks), 
systolic blood pressure was significantly decreased (228). Individuals (aged 65 ± 2 years) 
with isolated systolic hypertension displayed an improvement in endothelial NO production 
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and endothelial flow-mediated dilations after receiving alagebrium (oral gavage, 210 mg 
twice per day, 8 weeks) (229).  
Recent work indicates that alagebrium has the ability to scavenge MG in the test tube 
at a concentration ten-fold higher than MG (85), but whether alagebrium can reduce MG 
levels and prevent MG toxicity in biological system has not yet been firmly established. The 
cytotoxic effects of MG are mainly through formation of AGEs and/or ROS. We found that 
application of alagebrium completely prevented AGEs formation in MG-treated VSMCs, but 
only partially reduced MG-increased mitochondrial superoxide generation and intracellular 
nitrotyrosine levels (66). Moreover, treatment with alagebrium in STZ-diabetic rats or mice 
only partially or slightly reduced the excess formation of superoxide and peroxynitrite in the 
kidney (230, 231).  
 
1.6.3 RAGE blockade 
RAGE is a specific receptor expressed in a variety of cells, and the receptor-mediated 
effects significantly contribute to the cytotoxicity of AGEs. The anti-RAGE F(ab')2 [the 
blocking F(ab')2 fragments of RAGE antibodies] and soluble RAGE (sRAGE) are being 
considered to block AGEs-RAGE interaction (232). F(ab')2 fragments of RAGE antibodies 
were generated by pepsin digestion of the intact antibody. sRAGE is the extracellular ligand 
binding domain of RAGE. sRAGE may competitively react with various ligands of RAGE, 
such as AGEs, and block the ligand-RAGE interaction (49). Pretreatment of endothelial cells 
with anti-RAGE F(ab')2 inhibited the RAGE-mediated up-regulation of the inflammatory 
factor monocyte chemoattractant protein-1 (232). When the endothelial cells were treated 
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with anti-RAGE F(ab')2 or sRAGE, the AGEs-elevated expression of VCAM-1 and 
adhesivity of the monolayer for Molt-4 cells (a human acute lymphoblastic leukemia cell line) 
were inhibited (233). Moreover, in vivo usage of sRAGE improves diabetic vascular 
complications (234). For example, administration of sRAGE (2.25-5.15 mg/kg) blocked 
vascular permeability in the intestine, skin, and kidney of diabetic rats (49) and suppressed 
the hyperglycemia-induced atherosclerosis in STZ-treated apoE null mice (235).  
RAGE was initially identified as a receptor for AGEs (236), but it has also been 
shown to be a multi-ligand receptor which can recognize amyloid-beta peptide, β-sheet fibrils, 
S100/calgranulins, and Mac-1 (237). The blockage of RAGE may adversely affect 
ligand-induced signal transduction. For example, a recent study found that knockout of 
RAGE causes hyperactivity and increased sensitivity to auditory stimuli in mice (238).  
 
1.6.4 Over-expression of glyoxalase-I 
The effects of excess MG formation in cells can be inhibited by over-production of 
glyoxalase-I which converts α-dicarbonyl compounds, such as MG and glyoxal, to D-lactate 
with assistance of glyoxalase II and GSH. Over-expression of glyoxalase-I promoted MG 
metabolism to D-lactate and prevented the accumulation of MG and AGEs in bovine 
endothelial cells exposed to high glucose concentration (36). In glyoxalase-I transgenic 
Wistar rats, glyoxalase-I activity was increased ten- to fifty-fold in tissues (i.e. heart, kidney, 
eye, brain, aorta and skeletal muscle), and the hyperglycemia-elevated plasma MG, glyoxal 
and AGEs levels in STZ-induced diabetes were prevented (239). Over-expression of 
glyoxalase-I in Caenorhabditis elegans (C. elegans) attenuated aging-related MG and AGEs 
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accumulation, and extended its lifespan (81). Recently, C. elegans has been identified as a 
suitable model organism to study glucose toxicity (240). Feeding C. elegans with 40 mM 
glucose increased MG modification of mitochondrial proteins, elevated formation of ROS, 
and reduced its mean and maximum life span, but all of the above effects of high glucose 
were attenuated in glyoxalase-1 transgenic C. elegans (240).  
However, over-expression of glyoxalase-1 may lead to enhanced consumption or 
trapping of intracellular GSH, an important antioxidant in the body. Transfection of NIH-3T3 
cells with glyoxalase-1 cDNA increased cellular protein levels and activity of glyoxalase-1, 
but significantly reduced cellular GSH concentration (241). Reduction of GSH due to 
over-expression of glyoxalase-1 may limit the antioxidant capacity of cells and affect the 
activities of enzymes that use GSH as a cofactor. For example, over-expression of 
glyoxalase-1 in STZ-diabetic rats only partially counteracted the elevated oxidative stress 
levels, such as urine MDA and 8-isoprostane and kidney nitrotyrosine, and partially reversed 
the decreased protein levels of muscle mitochondrial complex I, II and III (239).   
 
1.6.5 Blockage of Aldolase A-glycolysis and Aldolase B-fructose pathway 
GA3P and DHAP are considered the major sources for endogenous MG generation (5, 
6). Glucose or fructose can be converted into GA3P and DHAP through the action of the 
enzyme aldolase A or/and aldolase B (7). SD rats fed with fructose increase MG formation in 
the serum and the aorta (72). Hyperglycemia activated the polyol pathway and increased 
production of sorbitol and fructose in the aorta, retina and kidney tissues of STZ-diabetic rats 
(242). Increased MG and AGEs production were observed in the blood, retina and kidney of 
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STZ-diabetic rats (87). However, whether blockage of aldolase A or aldolase B can prevent 
MG overproduction and related deleterious effects in different types of cells or in different 
animal models with metabolic syndrome has not been reported yet.  
 
1.7 Rationale and hypothesis 
Increased production of MG in vascular tissues is one of the causative factors for 
hypertension and vascular complications of diabetes. MG and MG-induced AGEs cause 
mitochondrial dysfunction, enhanced formation of ROS (superoxide and peroxynitrite), 
activation of NF-κB and increased Akt1-mediated proliferation in VSMCs and/or endothelial 
cells. High glucose is known to increase MG production in VSMCs and endothelial cells. MG 
production from VSMCs is also elevated in hypertension in the absence of hyperglycemia. 
Recently, MG has been found to impair the insulin signaling pathway in 3T3-L1 adipocytes, 
which is characterized by a reduction in insulin-mediated phosphoinositide 3-kinase (PI3K) 
pathway and glucose uptake (147). The underlying mechanisms for MG overproduction in 
insulin-insensitive VSMCs and insulin-sensitive adipose cells are unknown. Among the 
major pathways that lead to MG production is the glycolytic pathway in which glucose is 
metabolized to GA3P and DHAP through the involvement of aldolase A, and both GA3P and 
DHAP can spontaneously convert to MG.  Fructose, either derived from the diet (e.g., table 
sugar) or converted from glucose, can be catalyzed by aldolase B, a rate-limiting enzyme in 
fructose metabolism, to yield GA3P and DHAP and subsequently MG. 
Our working hypotheses are that the up-regulation of the fructose-AldoB pathway in 
VSMCs is a common mechanism for vascular MG overproduction in metabolic syndrome, 
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while the insulin-upregulated aldolase A-glycolysis pathway is responsible for enhanced MG 
production in adipose cells. Futhermore, it is hypothesized that inhibition of fructose-aldoB 
pathway suppresses MG-induced ROS and cellular dysfunction.  
 
1.8 Objectives and experimental approaches  
1.8.1 To evaluate the contribution of fructose and aldolase B to MG formation in 
cultured VSMCs and in the aorta of different rat models with metabolic syndrome.  
Whether fructose levels and aldolase B expression are elevated with the MG increase 
in the aorta in vivo in different rat disease models with metabolic syndrome was studied first. 
Aorta of rats with obesity, hypertension or diabetes were isolated, fructose and MG 
concentrations and gene expression of fructose transporter GLUT5 and enzymes involved in 
fructose metabolism, including aldose reductase (converting glucose to fructose through the 
polyol pathway), fructokinase (phosphorylating fructose to F-1-P), and aldolase B were 
measured. Gene expression of aldolase A, SSAO and CYP 2E1 which account for MG 
formation during glycolysis, protein and fatty acids metabolism, respectively, was examined. 
Thereafter, whether fructose levels and aldolase B expression are elevated by high 
glucose or fructose (25 mM) and responsible for excess MG production in cultured VSMCs 
was studied. Rat aortic smooth muscle cells (A-10 cells) were incubated with high glucose or 
fructose. Gene expression of aldolase A and aldolase B, cellular levels of G-6-P (the first 
metabolite of glycolysis), sorbitol (the first metabolite of polyol pathway), fructose, GA3P, 
DHAP and MG were measured. The inhibitors for aldose reductase, sorbitol dehydrogenase 
as well as shRNA targeting aldolase A and B were employed in VSMCs to compare the 
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Figure 1-6 Experimental design. The relative contributions of different pathways or 
enzymes to MG formation were evaluated by using enzyme inhibitors or siRNAs/shRNAs 
targeting aldolase A or aldolase B. Sorbinil, CP-470711, diallyl disulfide (DADS) and 
(E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974) are specific inhibitors for aldose 
reductase, sorbitol dehydrogenase, cytochrome P450 2E1 (CYP 2E1) and 
semicarbazide-sensitive amine oxidase (SSAO ), respectively. 2-Deoxy-D-glucose (2-DG) is 
a non-specific inhibitor for glucose uptake and hexokinase.      
 
Abbreviations: DHAP – dihydroxacetone phosphate; F-1-P – fructose 1-phosphate; F-1,6-P2 
– fructose-1,6-bisphosphate; G-6-P – glucose 6-phosphate; GA3P – glyceraldehyde 
3-phosphate; GLUT1, GLUT5 – glucose transporter 1 and 5, respectively; MG – 
methylglyoxal; TIM – triosephosphate isomerase.  
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relative contributions of these enzymes to high fructose or glucose-induced MG 
overproduction (Figure 1-6).    
Finally, the contribution of CYP 2E1 or SSAO to MG formation was evaluated. 
VSMCs were treated with acetone, glycine, or threonine (glycine and threonine are 
precursors of aminoacetone), and cellular MG levels were measured. The inhibitors for CYP 
2E1 and SSAO were applied to evaluate contributions of these enzymes to high fructose or 
glucose-induced MG overproduction in VSMCs.  
 
1.8.2 To investigate whether aldolase B knockdown prevents high glucose-induced MG 
overproduction and cellular dysfunction in endothelial cells.  
Endothelial cells were treated with high glucose (25 mM), and gene expression of 
aldolase B and cellular levels of MG were measured. Aldolase B siRNA was transfected into 
endothelial cells to knock down aldolase B. Levels of MG, AGEs, oxidative stress markers 
(oxidized DCF, H2O2, protein carbonyls and 8-oxo-dG), O-GlcNAc modification of proteins 
(product of hexosamine pathway), membrane PKC activity and amounts of nuclear NF-κB in 
control or aldolase B siRNAs-transfected cells were measured under normal (5 mM) or high 
glucose (25 mM) conditions.  
Whether MG can directly activate the metabolic and signaling pathways of glucose 
damage was investigated in endothelial cells treated with MG (30 or 100 µM). Moreover, 
whether aminoguanidine (a MG scavenger) or alagebrium (an AGEs breaker) prevents the 
high glucose-induced endothelial cell dysfunction was investigated.  
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1.8.3 To evaluate the contribution of insulin and aldolase A to MG formation in 
insulin-sensitive adipose cells 
3T3-L1 cells (a mouse embryonic fibroblast-adipose like cell line) were differentiated 
into adipocytes (>90% differentiation). Thereafter, these adipocytes were treated with insulin 
(100 nM) or high glucose (25 mM) or their combination for 12 h. Gene expression of 
aldolase A and aldolase B, and cellular levels of G-6-P, sorbitol, fructose and MG were 
measured and compared with their control group (glucose 5 mM). The inhibitors for 
glycolysis, aldose reductase, SSAO and CYP2E1 as well as siRNA targeting aldolase A or B 
were employed in adipocytes to compare the relative contributions of different pathways or 
enzymes to MG formation induced by insulin or high glucose. MG levels were also measured 
in 3T3-L1 adipocytes treated with fructose, ketone bodies (acetone and acetol), glycerol 
(converting to DHAP during triglycerides degradation (243)), glycine and threonine (glycine 
and threonine are precursors of aminoacetone) at a concentration of 25 mM in the absence or 
presence of 100 nM insulin.  
 
 
 
 
 
 
 
 
45 
 
 
 
 
CHAPTER 2 
 
GENERAL METHODOLOGY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
2.1 Animals  
All animal and experimental procedures were approved by the Animal Care 
Committee at The University of Saskatchewan, following guidelines of the Canadian Council 
on Animal Care. Male 4-week-old SD rats, 20-week-old WKY rats and SHR, and 
16-week-old lean, obese and diabetic Zucker rats were purchased from Charles River 
Laboratories (Quebec, Canada). 4-week-old SD rats were treated with or without 60% 
fructose (w/w in chow) for another 16 weeks to induce hypertension which was confirmed by 
blood pressure measurement. After starving for 10 h, the rats were anaesthetized with sodium 
pentobarbital (60 mg/Kg, i.p.) or isoflurane (5%, inhalation). The depth of anesthesia was 
evaluated by limb withdrawal reflexes. A supplemental dose of pentobarbital (30 mg/Kg, i.p.) 
or a longer time of isoflurane inhalation was applied if nessary until the rats’ reflexes 
disappeared. Blood was collected by cardiac puncture. Aorta from rats were collected and 
snap frozen in liquid nitrogen and stored at -80° C for further processing. Fasting serum 
glucose and insulin levels were measured using a glucose assay kit (Bioassay systems, 
Hayward, USA) and a rat-specific insulin ELISA kit (Mercodia AB, Sylveniusgatan, Uppsala, 
Sweden), respectively. Fasting serum fructose was measured by an enzymatic 
spectrophotometric assay (166).  
 
2.2 Cell culture  
Rat aortic smooth muscle cell line (A-10 cells) and mouse embryonic fibroblast- 
adipose like cell line (3T3-L1 fibroblast cells) were obtained from American Type Culture 
Collection. EA. hy926 cells, an endothelial cell line derived from the fusion of human 
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umbilical vein endothelial cells with A549 lung carcinoma cells (244), were a gift kindly 
provided by Dr. Cora-Jean Edgell, University of North Carolina at Chapel Hill. EA. hy926 
cells well retain endothelial phenotype and functions, such as expression of eNOS, and grow 
rapidly in culture without requirement for special growth factors, and thus are very often used 
as an in vitro model for endothelial cells (244-247). 
A-10 cells were cultured in low-glucose Dulbecco’s Modified Eagle Medium (DMEM, 
5 mM glucose, Sigma-Aldrich, Oakville, ON, Canada) containing 10% bovine serum (BS) 
and penicillin-streptomycin (PS, 1% v/v) at 37° C in a humidified atmosphere of 5% CO2 and 
95% air, as described previously (56). Cells were starved in BS-free medium for 24 h before 
different treatments.  
EA. hy926 cells were cultured in low-glucose DMEM supplemented with 10% fetal 
bovine serum (FBS) and PS (1% v/v) at 37° C in a humidified atmosphere of 5% CO2 and 95% 
air. EA. hy926 cells were starved in DMEM containing 0.5% FBS for 24 h before treatments.  
3T3-L1 fibroblast cells (preadipocytes) were cultured in high-glucose DMEM (25 
mM glucose, Sigma-Aldrich, Oakville, ON, Canada) containing 10% FBS and PS (1% v/v) at 
37° C in a humidified atmosphere of 5% CO2 and 95% air. The differentiation of 3T3-L1 
fibroblast cells to adipocytes was induced as described previously (248). At two days after 
confluence, cells were incubated with high-glucose DMEM (10 % FBS) containing 0.25 µM 
dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine, and 172 nM insulin for three days. 
The cell culture medium was changed every day. Thereafter, cells were cultured in 
high-glucose DMEM (10 % FBS) containing 172 nM insulin for 2 days and in high-glucose 
DMEM (10 % FBS) for 2-6 days till >90% of cells became adipocytes (the cell culture 
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medium was changed every two days). The differentiation was evaluated using Oil Red O 
staining. Cells were starved in FBS-free medium for 24 h before different treatments.  
 
2.3 Gene knockdown in cells 
Knockdown of aldolase A or B in A-10 cells was established by transfection with 
SureSilencing plasmid shRNAs purchased from Superarray (Frederick, MD, USA) according 
to manufacturer's instructions. The transfected cells were selected in low-glucose DMEM (10% 
BS) containing 600 μg/mL G418 for 2 weeks and the survivors were maintained in 
low-glucose DMEM (10% BS) containing 200 μg/mL G418. Gene knockdown was verified 
with real-time PCR assay.  
Knockdown of aldolase A or B in EA. hy926 cells or in 3T3-L1 adipocytes was 
established by 24-h transfection of cells with a siRNA pool (a mixture of 4 different siRNA 
duplexes, purchased from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) targeting 
aldolase A or B using DharmaFECT™ 4 Transfection Reagent (Thermo Fisher Scientific, 
Nepean, ON, Canada) or siRNA Transfection Reagent (Santa Cruz Biotechnology Inc., Santa 
Cruz, CA, USA), respectively. Gene knockdown was verified with real-time PCR assay.  
 
2.4 MG measurement  
MG levels were measured by derivatization of MG with o-phenylenediamine (o-PD), 
followed by quantification of the resulting quinoxaline, 2-methylquinoxaline (2-MQ), with 
high-performance liquid chromatography (HPLC).  
MG levels in A-10 cells, 3T3-L1 adipocytes, and rat tissues were determined with the 
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o-PD-based assay established by Chaplen et al. (249). Briefly, tissues were ground to a fine 
powder using a mortar and pestle in liquid nitrogen. Cells and ground tissues were sonicated 
(5 seconds, 3 times, on ice) and centrifuged at 12,000 rpm (10 min, 4°C). 240 μL supernatant 
was mixed with 60 μL of perchloric acid (PCA, 1 N), kept on ice for 10 min, and 
deproteinized by centrifuging at 12,000 rpm (10 min, 4°C). 180 μL supernatant was mixed 
with 90 μL of o-PD (100 mM) and incubated at room temperature in the dark for 3 h, 
followed by centrifugation at 12,000 rpm (5 min, 4°C). 180 μL supernatant was mixed with 
20 μL of 5-methylquinoxaline (5-MQ, internal standard) and analyzed by HPLC using a 
Hitachi D-7000 HPLC system (Hitachi, Ltd., Mississauga, ON, Canada). 100 μL of mixture 
was injected onto a HPLC column (Nova-Pak® C18 column, 3.9×150 mm, MA, USA) for 
analysis using a mobile phase buffer containing 17% acetonitrile, 8% 50 mM NaH2PO4 (pH 
4.5), and 75% water at a flow rate of 1 ml/min.  
It is well known that MG exists in a protein-bound form (99%), including reversibly 
and irreversibly bound forms, and in a free form (<1%) in biological samples (2). The 
irreversibly bound form of MG, such as AGEs, remains stable under the harsh assay 
conditions; however, the reversibly bound MG is in dynamic equilibrium with free MG and, 
therefore, it may release MG during sample treatment procedures and cause big variations in 
MG measurement (2, 250). To set up a standard protocol that yields consistent values of MG 
in a given biological sample, we modified Chaplen’s protocol (251). We increased the 
incubation time of cell extracts or blood with o-PD under an acidic environment which forces 
more reversibly bound MG to release and react with o-PD. Briefly, cells or ground tissues 
were sonicated three times for 5 seconds each time and centrifuged at 12,000 rpm (10 min, 
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4°C). 180 μL of the supernatant was incubated with 180 μL of PCA (1 N) and 40 μL of o-PD 
(100 mM) for 24 h at room temperature in the dark. The mixture was centrifuged at 12,000 
rpm (10 min, 4°C). 180 μL of the supernatant was mixed with 20 μL of 5-MQ, and analyzed 
by HPLC with a mobile phase buffer containing 17% acetonitrile, 8% 50 mM NaH2PO4 (pH 
4.5), and 75% water. For the blood sample, 135 μL of serum was incubated with 135 μL of 
PCA (1 N) and 30 μL of o-PD (100 mM) for 24 h at room temperature in the dark. The 
mixture was centrifuged at 12,000 rpm (10 min, 4°C). 180 μL of the supernatant was mixed 
with 20 μL of 5-MQ and analyzed by HPLC. This modified method has been used in our lab 
since 2009 for MG measurement, including MG levels in rat blood and in cultured EA. hy926 
cells. 
 
2.5 Measurement of glucose metabolites  
Cells or ground tissues were sonicated (5 seconds, 3 times, on ice) and centrifuged at 
12,000 rpm (10 min, 4°C). Total protein levels were determined with a bicinchoninic acid 
protein assay kit (Sigma-Aldrich, Oakville, ON, Canada). Intracellular fructose levels were 
measured by a fructose assay kit (BioVision, Mountain View, USA). Aliquots of supernatant 
were deproteinized by ¼ volume of PCA (1N) and neutralized by 2.5 M K2CO3 to measure 
the levels of glucose 6-phosphate and sorbitol using enzymatic fluorometric methods (252, 
253).  
 
2.6 Measurement of oxidative stress level  
Cells in 24 or 96-well plates were washed with phosphate buffered saline (PBS), and 
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the total intracellular ROS levels were stained with a non-specific ROS probe 
2',7'-dichlorodihydrofluorescein diacetate (DCF-DA, D399, purchased from Invitrogen, 
Burlington, ON, Canada) for 30 min at 5 µM. Intracellular H2O2 levels were stained with a 
specific fluorogenic H2O2 probe (Calbiochem, San Diego, CA, USA) for 30 min at 1 µM. 
DCF-DA or H2O2 probe were dissolved in dimethyl sulfoxide (DMSO) as a stock solution 
and the solution was diluted in PBS to the final concentration. DCF-DA is non-fluorescent. It 
can react with multiple forms of ROS, such as superoxide, H2O2 and ONOO
-
, to yield 
fluorescent DCF. The specific H2O2 probe is a monosulfonated non-fluorescent fluorescein 
ester compound which selectively reacts with H2O2 to produce fluorescein (254). The 
fluorescence intensities of each staining were analyzed with a Fluoroskan Ascent plate reader 
(Thermo LabSystem, Franklin, MA, USA). Protein oxidation was assessed by measuring 
total protein carbonyls with an immunoblot kit (Cell Biolabs Inc., San Diego, CA, USA). The 
DNA oxidation biomarker 8-oxo-dG was visualized by immunofluorescent staining and 
photographed under fluorescence microscopy, using a specific mouse monoclonal 8-oxo-dG 
antibody (Trevigen, Gaithersburg, MD, USA), following the manufacturer's instructions. 
 
2.7 Real-time Quantitative PCR (RT-PCR)  
Total RNA was isolated from A-10, EA. hy926 cells, and rat aorta using an RNeasy 
Mini Kit, and from 3T3-L1 adipose cells using an RNeasy Lipid Tissue Mini Kit (both kits 
were purchased from Qiagen sciences, Mississauga, ON, Canada). 1-2 μg of RNA are 
converted to cDNA with an iScript™ cDNA Synthesis Kit or iScript™ advanced cDNA 
Synthesis Kit (Bio-rad, Mississauga, ON, Canada). Real-time PCR was performed in an 
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iCycler iQ apparatus (Bio-Rad, Hercules, CA, USA) using SYBR Green PCR Master Mix 
(Bio-Rad) with primers listed in Table 2-1. All RT-PCRs were performed in triplicate in 
optical-grade PCR tubes or plates and running at 95°C for 30 s, 55°C for 1 min, and 72°C for 
30s for 45 cycles. Melting curves were acquired immediately after cycling.  
 
Table 2-1 RT-PCR primers for different mRNAs 
Gene Forward primer Reverse primer 
Rat aldolase A 5'-CCAACTGCTGCTGACTG-3' 5'-GGGCACTACACCCTTATC-
3' 
Mouse aldolase A 5'-CAACGGTCACAGCACTTC-
3' 
5'-CTTCCTCACTCTGCCCTC-3
' 
Rat aldolase B 5'-ACAGCCTCCTACACCTACT
-3' 
5'-GCTCATACTCGCACTTCA-3
' 
Mouse aldolase B 5'-CCAGTTCCCTATGTTCCA-3
' 
5'-TTGCTGTGCCTCTTCTAT-3' 
Human aldolase B 5'-AGCCTCGCTATCCAGGAA
AACG-3',  
5'-TGGCAGTGTTCCAGGTCA
TGGT-3' 
Rat CYP 2E1 5'-GGGAAACAGGGTAA-3' 5'-GCTCAGCAGGTAGAA-3' 
Rat β-actin 5'-CGTTGACATCCGTAAAGA
C-3' 
5'-TAGGAGCCAGGGCAGTA-3
' 
Human β-actin 5'-ACTTAGTTGCGTTACACCC
TT-3',  
5'-GTCACCTTCACCGTTCCA-
3' 
Primers of rat SSAO, GLUT5, aldose reductase, fructokinase and 18s rRNA, and mouse 18s 
rRNA were purchased from Qiagen Inc., Mississauga, ON, Canada   
 
2.8 Western blot 
Cells or tissues were lysed for 1 h in an ice-cold radioimmunoprecipitation assay 
buffer (RIPA, purchased from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) 
supplemented with 1% protease inhibitor cocktail solution (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA) and 1 mM phenylmethylsulfonyl fluoride (PMSF). After 
centrifugation at 12,000 rpm (10 min, 4°C), the supernatant was collected as total cell 
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proteins. Nuclear proteins were extracted as previously described (255). Total cell proteins 
(50 or 100 μg) or nuclear proteins (20 μg) were boiled with 2X SDS sample buffer (Bio-Rad, 
Mississauga, ON, Canada) for 5 min, resolved by 7.5-10 % SDS-PAGE, and transferred onto 
polyvinylidene fluoride (PVDF) membranes (Millipore Corp. Bedford, MA, USA). The 
membranes were blocked in 5% milk powder in PBST (PBS containing 0.1% Tween 20) for 
30 min, and incubated for 3 h at room temperature or overnight at 4°C with primary 
antibodies as follows: aldolase A (1:5000, Sigma-Aldrich, Oakville, ON, Canada), aldolase B 
(1:500, Epitomics Inc., Burlingame, CA, USA), O-GlcNAc (RL2) (1:1000, Thermo Fisher, 
Nepean, ON, Canada), aldose reductase (1:500, Santa Cruz), β-actin (1:5000, Santa Cruz ), 
α-tubulin (1:500, Santa Cruz), NF-κB (p65) (1:500, Santa Cruz) and lamin B (1:1000, Santa 
Cruz Biotechnology Inc., Santa Cruz, CA, USA), respectively. Membranes were washed with 
PBST for 4-5 times and incubated with horse radish peroxidase conjugated secondary 
antibodies (1:2000-1:1000, Upstate, Waltham, MA, USA) for 3 h at room temperature. The 
protein bands were visualized with enhanced chemiluminescence reagents (Amersham 
Biosciences, Pistcataway, NJ, USA) and exposed to X-ray film (Santa Cruz Biotechnology 
Inc., Santa Cruz, CA, USA).  
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3.1 Abstract 
Aims Methylglyoxal (MG) overproduction has been reported in metabolic syndrome with 
hyperglycemia (diabetes) or without hyperglycemia (hypertension), and the underlying 
mechanism was investigated.  
Methods and results Contributions of different pathways or enzymes to MG formation were 
evaluated in aorta or cultured vascular smooth muscle cells (VSMCs). In all four animal 
models of metabolic syndrome, i.e. chronically fructose-fed hypertensive Sprague–Dawley 
rats, spontaneously hypertensive rats, obese non-diabetic Zucker rats, and diabetic Zucker 
rats, serum and aortic MG and fructose levels were increased, and the expression of GLUT5 
(transporting fructose) and aldolase B (converting fructose to MG) in aorta were up-regulated. 
Aortic expressions of aldolase A, semicarbazide-sensitive amine oxidase (SSAO), and 
cytochrome P450 2E1 (CYP 2E1), accounting for MG formation during glycolysis, protein, 
and lipid metabolism, respectively, was unchanged/reduced. Fructose (25 mM) treatment of 
VSMCs up-regulated the expression of GLUT5 and aldolase B and accelerated MG 
formation. Insulin (100 nM) increased GLUT5 expression and augmented fructose-increased 
cellular fructose accumulation and MG formation. Glucose (25 mM) treatment activated the 
polyol pathway and enhanced fructose formation, leading to aldolase B up-regulation and 
MG overproduction. Inhibition of the polyol pathway reduced the glucose-increased aldolase 
B expression and MG generation. The excess formation of MG in under these conditions was 
eliminated by knock-down of aldolase B, but not by knock-down of aldolase A or inhibition 
of SSAO or CYP 2E1.  
Conclusion Up-regulation of aldolase B by accumulated high fructose is a mechanism for 
56 
 
MG overproduction in VSMCs and aorta in different models of metabolic syndrome. 
Key words Aldolase B, Fructose, Methylglyoxal, Metabolic syndrome 
 
3.2 Introduction 
Increased levels of methylglyoxal (MG) and MG-glycosylated proteins or advanced 
glycation endproducts (AGEs) are the key pathogenic event in the vascular dysfunction in 
diabetes and hypertension (106, 131, 256). MG induces mitochondrial dysfunction and 
increases production of superoxide and peroxynitrite in vascular smooth muscle cells 
(VSMCs) (55, 66). The interaction between MG and hydrogen sulfide, a natural vasorelaxant, 
in VSMCs has been also reported (257). However, the underlying mechanism for MG 
overproduction was unknown. 
MG is generated through several metabolic pathways. Spontaneous non-enzymatic 
fragmentation of triosephosphates, glyceraldehyde 3-phosphate (GA3P) and dihydroxyacetone 
phosphate (DHAP), is a primary source for endogenous MG generation (5, 6). Increased GA3P 
and DHAP generation, in turn, may occur due to increased availability of glucose and fructose. 
In the cytosol, glucose is metabolized enzymatically through the glycolytic pathway into 
fructose-1,6-bisphosphate (F-1,6-P2), which subsequently forms GA3P and DHAP catalyzed 
by aldolase A (7). On the other hand, fructose, either derived from the diet (e.g., table sugar) or 
converted from glucose by aldose reductase and sorbitol dehydrogenase via the polyol pathway, 
can be phosphorylated by fructokinase to fructose 1-phosphate (F-1-P), which is cleaved by 
aldolase B to generate glyceraldehyde and DHAP (7). Other potential sources of MG include 
the oxidation of aminoacetone (generated during protein catabolism) by semicarbazide- 
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sensitive amine oxidase (SSAO) and the oxidation of acetone (generated from lipolysis) by 
cytochrome P450 2E1 (CYP 2E1) (10).   
Most glucose is physiologically metabolized through glycolytic pathway to GA3P and 
DHAP, and, therefore, MG is traditionally considered an intrinsic metabolite of glycolysis 
(258). High levels of glucose with accumulation of endogenous MG have received much 
attention in diabetes research due to the potentially pathogenic roles of MG and AGEs in the 
development of diabetes and diabetic complications (106). However, the importance of 
glycolysis in MG overproduction during hyperglycemia is challenged because high levels of 
glucose did not change or even impair glycolysis, but it activated the polyol pathway and 
enhanced fructose production in diabetic states (242, 259, 260). Moreover, elevated MG 
levels are also present in the metabolic syndrome without hyperglycemia, such as 
hypertension (131). As spontaneously hypertensive rats (SHR) develop hypertension, MG 
levels in plasma and aorta increase in an age-dependent fashion (131), although no difference 
in blood glucose levels between SHR and control rats is apparent (132). When Sprague 
Dawley (SD) rats were fed with fructose for 16 weeks, elevated MG levels in the serum and 
the aorta with development of vascular remodeling and high blood pressure was evident (25), 
but plasma glucose levels were within physiological ranges (147). Indeed, fructose treatment 
directly increased levels of MG in cultured VSMCs (73). Aldolase B is a rate-limiting 
enzyme in fructose metabolism, and a deficiency of aldolase B results in fructose intolerance 
in humans (157, 261, 262). These observations raise an important question whether fructose 
and aldolase B are commonly and predominantly responsible for vascular MG 
overproduction in metabolic syndrome with normal blood glucose, such as hypertension and 
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obesity, and with hyperglycemia, such as diabetes.  
In this study, different rat models including fructose-fed SD, SHR, obese and diabetic 
Zucker rats, and their respective controls, were used to investigate the involvement of 
fructose and aldolase B in MG formation in vivo. The gene expression of enzymes (aldose 
reductase, fructokinase, aldolase A, aldolase B, SSAO, and CYP 2E1) and glucose transporter 
5 (GLUT5), a specific fructose transporter (263), was examined in the aorta from these rats 
and in cultured VSMCs (the major cellular constituent of aorta) after treatment with fructose 
or glucose. The inhibitors for aldose reductase, sorbitol dehydrogenase, SSAO, and CYP 2E1 
as well as shRNA targeting aldolase A and B were employed in VSMCs to compare the 
relative contributions of these enzymes to fructose or glucose-induced MG overproduction.  
 
3.3 Methods 
3.3.1 Animal Studies 
All animal and experimental procedures complied with the Guide for the Care and 
Use of Laboratory Animals published by the US National Institutes of Health (NIH 
Publication no. 85–23, revised 1996) as well as the Directive 2010/63/EU of the European 
Parliamen, and were approved by the Animal Care Committee at The University of 
Saskatchewan, following guidelines of the Canadian Council on Animal Care. Male 
4-week-old SD rats, 20-week-old Wistar-Kyoto (WKY) and SHR, and 16-week-old lean, 
obese and diabetic Zucker rats were purchased from Charles River Laboratories. 4-week-old 
SD rats were treated with or without 60% fructose (in chow) for another 16 weeks. Rats were 
anaesthetized with sodium pentobarbital (60 mg/Kg, i.p.) or isoflurane (5%, inhalation). The 
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depth of anesthesia was evaluated by limb withdrawal reflexes. A supplemental dose of 
pentobarbital (30 mg/Kg, i.p.) or a longer time of isoflurane inhalation was applied until the 
rats’ reflexes disappeared. Then the rats were euthanized by exsanguination, involving 
collection of blood from the heart, under deep anaesthesia, and their tissues were quickly 
collected. Serum glucose and insulin levels were measured using a glucose assay kit 
(Bioassay systems, Hayward, USA) and a rat-specific insulin ELISA kit (Mercodia AB, 
Sylveniusgatan, Uppsala, Sweden), respectively. Serum fructose was detected with a method 
based on fructose dehydrogenase (166), after deproteinization with ¼ volume of 1 N 
perchloric acid (PCA) and neutralization with 2.5 M K2CO3.  
 
3.3.2 Cell culture  
A-10 cells, a rat aortic smooth muscle cell line, were cultured in Dulbecco's modified 
Eagle medium containing 10% bovine serum. Sub-confluent (80%) VSMCs were starved for 
24 h in bovine serum-free Dulbecco's modified Eagle medium before further treatments in 
Dulbecco's modified Eagle medium containing 10% bovine serum.  
 
3.3.3 Plasmid small hairpin RNA (shRNA) knockdown of aldolase A or aldolase B  
Knockdown of aldolase A or B was established by transfection of A-10 cells with 
SureSilencing plasmid shRNAs (aldolase A, CACTGCCAATAAACAGCTATT; aldolase B, 
CTAGAGCACTGCCAGTATGTT; and control, GGAATCTCATTC GATGCATAC). The 
transfected cells were selected in medium containing 600 µg/mL G418 for 2 weeks and the 
survivors were maintained in 200 µg/mL G418. Gene knockdown was verified with real-time 
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PCR and Western blotting according to manufacturer's instructions (SuperArray, Frederick, 
MD, USA).  
 
3.3.4 MG Measurement  
MG levels in the aorta and VSMCs were determined with a o-phenylenediamine 
(o-PD)-based assay (249). Briefly, samples were sonicated and centrifuged at 12,000 rpm (10 
min, 4°C). 240 μL supernatant was mixed with 60 μL of PCA (1 N), kept on ice for 10 min, 
and deprotenized by centrifuging at 12,000 rpm (10 min, 4°C). Then 180 μL supernatant was 
incubated with 90 μL o-PD (100 mM) for 3 h at room temperature in the dark. The mixture 
was centrifuged at 12,000 rpm (5 min, 4°C). A portion of the supernatant (180 μL) was mixed 
with 20 μL of 5-methylquinoxaline (5-MQ, internal standard) and analyzed by 
high-performance liquid chromatography (HPLC) with a mobile phase buffer containing 17% 
acetonitrile, 8% NaH2PO4 (50 mM, pH 4.5), and 75% water.  
MG levels in serum were determined using our recently modified method (251). 
Briefly, 135 μL serum was incubated with 135 μL PCA (1 N) and 30 μL o-PD (100 mM) for 
24 h at room temperature in the dark. The mixture was centrifuged at 12,000 rpm (10 min, 
4°C). 180 μL of the supernatant was mixed with 20 uL 5-MQ and analyzed by HPLC. 
 
3.3.5 Biochemical assays 
Cell or tissue samples were sonicated and centrifuged at 12,000 rpm (10 min, 4°C). 
Total protein levels were determined with a bicinchoninic acid protein assay kit 
(Sigma-Aldrich, Oakville, ON, Canada). Intracellular fructose levels were measured by a 
61 
 
fructose assay kit (BioVision, Mountain View, USA). Aliquots of supernatants were 
deproteinized by ¼ volume of PCA (1N) and neutralized by 2.5 M K2CO3 to measure the 
levels of glucose 6-phosphate, sorbitol, GA3P and DHAP using the enzymatic fluorometric 
methods (252, 253). Glyoxalase 1 or 2 activity was assayed by using a spectrophotometric 
method to monitor the increase and decrease of S-D-lactoylglutathione, respectively, as 
described (264).  
 
3.3.6 Analysis of gene expression 
Total RNA was isolated using an RNeasy Mini Kit (Qiagen Inc., Mississauga, ON, 
Canada) and converted to cDNA with an iScript™ cDNA Synthesis Kit (Bio-rad, 
Mississauga, ON, Canada). Real-time PCR was performed using SYBR Green PCR Master 
Mix (Bio-Rad) with the following primers: rat aldolase A forward 
5'-CCAACTGCTGCTGACTG-3', reverse 5'-GGGCACTACACCCTTATC-3'; aldolase B 
forward 5'-ACAGCCTCCTACACCTACT-3', reverse 5'-GCTCATAC TCGCACTTCA-3'; 
CYP 2E1 forward 5-GGGAAACAGGGTAA-3, reverse 5-GCTCAGCAGGTAGAA-3; 
β-actin forward 5'-CGTTGACATCCGTAAAGAC-3', reverse 
5'-TAGGAGCCAGGGCAGTA-3'. Primers of aldolase A and B to verify shRNA knockdown 
were provided by Superarray (Frederick, MD, USA). Primers of SSAO, GLUT5, aldose 
reductase, and fructokinase were purchase from Qiagen (Mississauga, ON, Canada). Protein 
levels were analyzed by Western blotting using antibodies as follows: aldolase A (1:5000, 
Sigma-Aldrich, Oakville, ON, Canada), aldolase B (1:500, Epitomics Inc., Burlingame, CA, 
USA), and β-actin (1:5000, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).  
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3.3.7 Materials  
Sorbinil and CP-470711 were generous gifts from Pfizer Inc. (Groton, CT). Diallyl 
disulfide (DADS) was purchased from Sigma-Aldrich (Oakville, ON, Canada). 
(E)-2-(4-fluorophenethyl)-3- fluoroallylamine (MDL-72974) was a generous gift from Dr. 
Peter Yu (Department of Pharmacology, University of Saskatchewan, Canada). 
 
3.3.8 Statistics 
Data are expressed as mean ± SEM from at least 4 mice (n≥4) or from at least five 
independent experiments in cell study (n≥5/each group). Statistical analyses were performed 
using by parametric Student's t-test (two-tailed) or one-way ANOVA followed by Tukey's 
post-hoc test. 
 
3.4 Results  
3.4.1 Up-regulation of aldolase B and increased MG levels in fructose-fed hypertensive 
SD rats  
A previous study in our lab indicated that chronically fructose-fed SD rats displayed a 
normal fasting blood glucose but increased serum and aortic MG levels with the development 
of hypertension and insulin resistance (25, 147). To determine why fructose resulted in MG 
overproduction, we focused on the fructose-related transport and metabolic pathway. We 
observed that in addition to increased MG and fructose levels in the aorta (Figure 3-1A), 
16-week fructose feeding of SD rats raised mRNA levels of GLUT5, but had no effect on 
mRNA levels of aldose reductase (Figure 3-1B). Because our in vitro studies found that 95% 
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of GA3P or 26% of DHAP converted to MG non-enzymatically after 12-h incubation (Figure 
3-S1), we investigated whether fructose feeding affects gene expression of aldolase B which 
cleaves F-1-P to generate glyceraldehyde and DHAP. As shown in Figure 3-1C, fructose 
feeding elevated mRNA levels of aldolase B in the aorta, but had no effect on the mRNA 
levels of aldolase A, SSAO and CYP 2E1. In addition, fructose feeding up-regulated aortic 
mRNA levels of fructokinase, an enzyme that phosphorylates fructose into F-1-P (Table 
3-S1).  
 
3.4.2 Increased fructose, aldolase B mRNA and MG levels in SHR   
SHR and WKY rats at age of 20 weeks displayed similar levels of serum glucose; 
however, serum MG, fructose, and insulin levels were markedly increased in SHR (Table 3-1). 
Increased levels of MG and fructose, and up-regulated mRNA expression of GLUT5 and 
unaltered mRNA expression of aldose reductase, were observed in the aorta of SHR 
compared to WKY (Figures 3-1D, 3-1E). SHR had higher levels of fructokinase and aldolase 
B mRNA in the aorta than WKY rats (Table 3-S1, Figure 3-1F). Both SHR and WKY rats 
displayed similar mRNA levels of aldolase A and CYP 2E1 in the aorta, but SHR had lower 
levels of SSAO mRNA than WKY rats (Figure 3-1F).  
 
3.4.3 Increased fructose, aldolase B mRNA and MG levels in obese, non-diabetic Zucker 
rats 
When compared with lean rats, obese rats had similar levels of serum glucose but 
much higher levels of serum MG and insulin (Table 3-1). Serum fructose levels in obese rats 
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were increased (Table 3-1), although not significantly. Obese rats displayed higher levels of 
MG and fructose as well as up-regulated mRNA expression of GLUT5, fructokinase and 
aldolase B in the aorta (Figures 3-2A, 3-2B and 3-2D). However, aortic mRNA levels of 
aldose reductase, aldolase A, SSAO, and CYP 2E1 were not significantly different in obese 
and lean rats (Figures 3-2C, 3-2D).   
 
3.4.4 Activation of polyol pathway and increased fructose, MG levels in diabetic Zucker 
rats  
In comparison with obese rats, diabetic rats had similar but exacerbated alterations. 
Diabetic rats exhibited higher levels of fructose and MG in serum and the aorta as well as 
higher levels of aldolase B mRNA in the aorta than non-diabetic lean and obese rats (Table 
3-1, Figs. 2A, 2D). Aortic mRNA levels of GLUT5 and fructokinase in diabetic rats were 
higher than those in lean rats but not significantly different than those in obese rats (Figure 
3-2B). Unlike obese, hypertensive, and fructose-fed rats, diabetic rats displayed higher 
glucose and lower insulin levels in serum (Table 3-1). We also investigated whether the 
polyol pathway is involved in aortic fructose and MG overproduction in diabetic Zucker rats. 
As shown in Figure 3-2C, aortic levels of aldose reductase mRNA and sorbitol were higher in 
diabetic rats than non-diabetic lean and obese rats. In contrast, mRNA levels of aldolase A 
were decreased in diabetic rats (Figure 3-2D).  
 
3.4.5 MG accumulation in VSMCs induced by fructose, fructose plus insulin, or glucose    
To investigate whether fructose and aldolase B are primarily responsible for increased 
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MG levels in the aorta in the different rat models, cultured A-10 cells were used. We chose 
glucose at 25 mM to mimic the hyperglycemia of diabetics and chose fructose at 25 mM for 
comparative purposes. We observed that fructose (25 mM) induced time-dependent increases 
of cellular MG and fructose (Figures 3-3A, 3-3C). In the presence of insulin (100 nM), the 
cellular MG and fructose levels induced by fructose (25 mM, 6 and 12 h) were further 
augmented (Figures 3-3B, 3-3C). Insulin alone (100 nM) had no effect on cellular levels of 
MG and fructose (Figures 3-3B, 3-3C). Glucose (25 mM) also increased cellular MG and 
fructose levels in a time-dependent manner (Figures 3-3A, 3-3C). Application of insulin (100 
nM) had no effect on cellular fructose levels induced by glucose (25 mM) (Figure 3-3C). In 
comparison with glucose (25 mM), fructose at the same concentration raised MG and 
fructose levels in a similar pattern but which started earlier (<3 h), reached the peak quicker, 
and stayed at elevated levels longer (~18 h).  
We explored whether or not glucose or fructose induces a change of glyoxalase 1 and 
glyoxalase 2 activities because most of the cellular MG was degraded by these two enzymes 
into D-lactic acid (264). Glucose (25 mM), fructose (25 mM), or fructose plus insulin (100 
nM) incubations of cultured A-10 cells increased the activity of glyoxalase 1 but not 
glyoxalase 2 after 12-h treatment, and increased the activity of both glyoxalase 1 and 
glyoxalase 2 after 24-h treatment (Figure 3-3D). 
 
3.4.6 Fructose or fructose plus insulin-enhanced MG formation was totally prevented by 
aldolase B knockdown in VSMCs 
After the cells were treated with fructose (25 mM) and insulin (100 nM), respectively, 
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we observed a similar rise in mRNA levels of GLUT5; with co-treatment of fructose and 
insulin, the GLUT5 mRNA was further elevated (Figure 3-4A). Fructose (25 mM) 
up-regulated the gene expression of fructokinase (mRNA) and aldolase B (mRNA and protein) 
but had no effect on aldolase A mRNA (Figures 3-4A - 3-4C). In the presence of insulin (100 
nM), fructose-elevated fructokinase and aldolase B gene expression were further raised 
(Figures 3-4A - 3-4C). Insulin alone had no effect on fructokinase mRNA, aldolase A mRNA, 
and aldolase B mRNA and protein levels (Figures 3-4A - 3-4C). Transfection with shRNA 
targeting aldolase B successfully knocked-down aldolase B in A-10 cells, which reduced 
aldolase B mRNA by 75 % and protein by 84% compared to the transfection with control 
shRNA (Figure 3-4D). In these cells transfected with aldolase B shRNA, the increases in 
cellular MG production induced by fructose (25 mM) or fructose plus insulin (100 nM) were 
completely inhibited (Figure 3-4D).   
 
3.4.7 Glucose-increased MG formation was reduced by inhibition of polyol pathway and 
totally prevented by knockdown of aldolase B in VSMCs 
Treatment with glucose (25 mM, 12 h) elevated levels of polyol pathway metabolites 
sorbitol and fructose, as well as GA3P, DHAP and MG in A-10 cells, but unchanged levels of 
G-6-P (Figures 3-3C, 3-5A). The glucose-increased MG levels were reduced in the presence 
of sorbinil (a specific aldose reductase inhibitor) and CP-470711 (a specific sorbitol 
dehydrogenase inhibitor) (Figure 3-5B). Glucose (25 mM, 12 h) up-regulated aldolase B 
expression but down-regulated aldolase A expression in mRNA and protein levels (Figures 
3-5C, 3-5D). The down-regulation of aldolase A and up-regulation of aldolase B evoked by 
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glucose (25 mM) were reduced in the presence of sorbinil, CP-470711, or their combination 
(Figures 3-5C, 3-5D). MG levels were raised in control shRNA cells treated with glucose (25 
mM) vs. glucose (5 mM, 12 h). However, high glucose-increased MG levels were totally 
abolished by transfection with aldolase B shRNA (Figure 3-5E). Transfection with aldolase A 
shRNA reduced aldolase A mRNA (by 69%) and protein levels (by 86%) in A-10 cells 
(Figure 3-5E), but this aldolase A knockdown only partially inhibited glucose-induced MG 
overproduction (Figure 3-5E). Basal cellular MG levels in normal glucose (5 mM)-treated 
VSMCs were unchanged by application of sorbinil or CP-470711, or by knockdown of 
aldolase B, but reduced by knockdown of aldolase A (Figures 3-5A, 3-5E).      
 
3.4.8 CYP 2E1 and SSAO are not implicated in MG formation in VSMCs  
Treatment with acetone, glycine, or threonine (glycine and threonine are precursors of 
aminoacetone) at 25 mM for 3, 12, or 24 h did not alter MG levels in A-10 cells (Figure 3-S2). 
Co-application of DADS or MDL-72974, the specific inhibitor of CYP 2E1 and SSAO, 
respectively, for 12 h had no effect on basal MG formation induced by normal glucose (5 mM) 
and excess MG production induced by high glucose (25 mM), fructose (25 mM), or high 
fructose plus insulin (100 nM) (Figure 3-S2).  
 
3.5 Discussion  
The functional alterations induced by increased MG in the aorta in vivo or VSMCs in 
vitro have been shown in numerous studies from our lab. For example, we observed 
mitochondrial dysfunction, increased oxidative stress, and enhanced proliferation in cultured 
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VSMCs treated with MG (38, 55, 66). MG injection (iv/ip) induced endothelial dysfunction, 
such as decreases in eNOS activity, NO production, and endothelium-dependent relaxation, in 
the aorta of SD rats (70). Using MG scavengers, Dr Wu’s group found that the over-produced 
MG contributed to the vascular remodeling in hypertensive rats (25, 72). With all these 
functional studies having been done, the focus and the novelty of the present study are to 
illustrate the molecular mechanisms for vascular MG overproduction and this study 
demonstrated that up-regulation of aldolase B by increased fructose is a common and primary 
mechanism for the increased MG production in vascular tissues, including both smooth 
muscle cells and endothelial cells, in different metabolic syndrome (obesity, hypertension, 
and diabetes), despite their varying blood glucose and insulin levels. Evidence supporting our 
hypothesis includes the observations that: 1) In all 4 rat models of metabolic syndrome, levels 
of fructose and MG in the serum and the aorta were increased; gene expression of aldolase B, 
but not aldolase A, SSAO and CYP 2E1, in the aorta were up-regulated; 2) in cultured 
VSMCs, glucose (25 mM), fructose (25 mM), or fructose plus insulin (100 nM) elevated 
cellular fructose accumulation, up-regulated aldolase B gene expression and increased MG 
formation; excess MG formation under these conditions was all completely inhibited by 
knockdown of aldolase B, but not by knockdown of aldolase A or inhibition of SSAO or CYP 
2E1.     
Because high-fructose diets impair vascular relaxation and increase blood pressure in 
arteries (265, 266), the role of fructose in cardiovascular diseases is gradually receiving more 
attention. We observed that rat models of hypertension or obesity showed normoglycemia but 
higher levels of fructose and MG in serum than their respective controls (Table 3-1). 
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Increased mRNA level of fructose transporter GLUT5 was found in VSMCs treated with 
fructose (25 mM) and in the aorta of fructose-fed rats, SHR, and obese Zucker rats (Figures 
3-1, 3-2), which may, in turn, facilitate more fructose entering VSMCs. Fructose is well 
known as a precursor of MG in VSMCs and the aorta (25, 73, 146). Our data indicate that the 
increased circulating fructose levels in the serum and the subsequent fructose accumulation in 
the aorta could be the cause for aortic MG overproduction in metabolic-syndrome rats 
without hyperglycemia.  
Insulin is likely to promote fructose-induced cellular fructose and MG accumulation 
in hypertension and obesity. High levels of insulin and fructose but normal glucose in serum 
were observed in obese (obese Zucker) and hypertensive (SHR) rats (Table 3-1), and, as 
previously reported, in rats fed with fructose (266, 267). Indeed, many clinical studies report 
a similar phenomenon in obese or hypertensive patients who have normal glucose 
(normoglycemia) but high insulin (hyperinsulinemia) (188-190). In VSMCs, we observed 
that fructose-elevated levels of cellular MG and gene expression of fructokinase (mRNA) and 
aldolase B (mRNA and protein) were further augmented in the presence of insulin (100 nM), 
although insulin alone had no effect on the expression of these enzymes, neither on cellular 
fructose and MG formation (Figures 3-3, 3-4). One possible reason for this increase in 
fructose-induced MG production induced by insulin is that insulin may up-regulate GLUT5 
expression and by doing so, when extracellular fructose is increased, to enhance fructose 
transport and accumulation in cells. Our data showed that insulin alone up-regulated GLUT5 
expression, and application of insulin augmented fructose-increased GLUT5 mRNA levels 
and cellular fructose accumulation in VSMCs (Figures 3-3, 3-4). Thus, hyperinsulinemia may 
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augment fructose-enhanced MG formation in obese and hypertensive rats through its 
up-regulation of GLUT5 rather than its effect on fructose catabolism.  
A role for aldolase B in fructose accumulation-induced MG overproduction seems 
paramount. Aldolase B splits F-1-P, phosphorylated product of fructose, into MG precursors 
glyceraldehyde and DHAP, and plays a rate-limiting role in fructose metabolism (261, 262). 
Our data supported that elevated MG levels are associated with up-regulated fructose 
metabolism pathway, especially the key enzyme aldolase B in aorta of fructose-induced or 
genetic hypertensive, or obese non-diabetic rats (Figures 3-1, 3-2). Since GA3P and DHAP 
are considered direct sources for endogenous MG formation (5, 6) and showed high 
efficiencies of non-enzymatic conversion to MG (Figure 3-S1), our study suggests that 
up-regulation of aldolase B expression in metabolic syndrome is the triggering event for 
fructose accumulation-induced MG overproduction. However, aortic gene expression of 
aldolase A, SSAO and CYP 2E1, which are responsible for MG formation during glycolysis, 
protein and lipid metabolism, respectively, were unchanged or even reduced in these 
hypertensive or obese rats (Figures 3-1, 3-2). Our in vitro studies with cultured VSMCs 
treated with fructose or fructose plus insulin, a condition mimicking hypertension and obesity, 
also identify a major role of aldolase B in fructose-induced excess MG formation. High 
fructose (25 mM) concentration significantly increased mRNA and protein levels of aldolase 
B in VSMCs (Figure 3-4). As mentioned earlier, insulin (100 nM) can increase fructose 
transport and augment fructose-enhanced aldolase B expression, although insulin alone has 
no effects on aldolase B expression (Figure 3-4). In the VSMCs with aldolase B knockdown, 
the excess MG production induced by fructose or fructose plus insulin was totally prevented 
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(Figure 3-4). These observations in vivo and in vitro indicate that fructose accumulation and 
up-regulated aldolase B expression is mainly responsible for the aortic MG over-generation 
in obesity and hypertension without hyperglycemia.   
Fructose and MG formation in diabetic rats seems more complicated. Diabetic Zucker 
rats had higher fructose and glucose (hyperglycemia), but lower insulin (hypoinsulinemia) 
levels in serum than both lean and obese rats (Table 3-1), similar to clinical observations in 
diabetic patients (162, 268). Glucose can metabolize to fructose via the polyol pathway (106). 
Diabetic rats displayed an up-regulation of GLUT5 and an activation of polyol pathway 
(evident by the elevated levels of aldose reductase mRNA and sorbitol) in the aorta when 
compared with non-diabetic lean and obese rats (Figure 3-2), indicating that both increased 
serum fructose and glucose contribute to aortic fructose formation. These diabetic rats showed 
exacerbated alterations in fructose accumulation, aldolase B expression and MG formation 
compared with non-diabetic obese and hypertensive rats (Figures 3-1, 3-2). However, mRNA 
levels of aldolase A, SSAO and CYP 2E1 were unchanged or even reduced in the aorta of 
diabetic rats. Our data suggest that fructose and aldolase B also predominantly contribute to 
MG overproduction in metabolic syndrome with hyperglycemia.   
Most glucose is physiologically metabolized through the glycolytic pathway and the 
traditional view regards glucose-induced MG formation as a result of glycolysis (258). We 
indeed observed that the basal cellular MG levels in glucose (5 mM)-treated cells were 
reduced by shRNA knockdown of aldolase A, but not affected by knockdown of aldolase B or 
inhibition of polyol pathway, SSAO or CYP 2E1 (Figures 3-5, 3-S2), indicating a critical role 
for aldolase A and glycolysis in the maintenance of basal MG levels under normoglycemic 
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conditions, as shown in the aorta of untreated SD, WKY, and lean Zucker rats. However, 
hyperglycemia developing in diabetes is unlikely to increase metabolism through glycolysis in 
vascular cells (259, 260). In this work, we found that the levels of G-6-P, the first metabolite of 
glycolysis, in VSMCs treated with glucose at concentrations of 5 and 25 mM were not 
significantly affected (Figure 3-5). The gene expression of aldolase A was decreased in 
VSMCs treated with high glucose (Figure 3-5). In contrast, high glucose (25 mM) elevated 
cellular levels of polyol pathway metabolites sorbitol and fructose, up-regulated aldolase B 
expression, and increased GA3P, DHAP as well as MG formation (Figures 3-3, 3-5). High 
glucose induced a time-dependent increase of cellular MG and fructose but in a considerably 
delayed pattern compared to fructose treatment (Figure 3-3). Inhibition of aldose reductase 
and/or sorbitol dehydrogenase reduced glucose-elevated aldolase B expression and MG levels 
in VSMCs (Figure 3-5). More importantly, glucose-induced excess MG generation was 
completely prevented by shRNA knockdown of aldolase B in VMSCs, but only partially 
reduced by shRNA of aldolase A and not affected by inhibitor of SSAO or CYP 2E1 (Figures 
3-5, 3-S2). These findings provide direct evidence that, in the hyperglycemic condition, the 
polyol pathway but not the glycolytic pathway was activated, and subsequently fructose is 
accumulated and aldolase B is up-regulated, resulting in excess MG formation in VSMCs.  
In conclusion and as shown in Figure 3-6, with normoglycemia and normal levels of 
fructose and insulin, aortic glucose is metabolized through the glycolytic pathway, which 
results in basal levels of MG formation in lean Zucker, SD, and WKY rats. However, the 
situation changes with metabolic syndrome. With normoglycemia but increased serum 
fructose, aortic GLUT5 mRNA levels are up-regulated by fructose, and, as a consequence, 
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fructose levels in the aorta are elevated. Increased fructose up-regulates the gene expression 
of fructokinase and aldolase B, leading to increased fructose metabolism and excess MG 
generation in the aorta of obese Zucker, SHR, and fructose-fed SD rats. Serum insulin is also 
increased in obese or hypertensive rats, which may promote fructose transport and MG 
generation in the aorta by up-regulating GLUT5. When hyperglycemia with high levels of 
fructose but low levels of insulin in the serum are established in diabetes, much higher 
increases in fructose metabolism and MG formation are observed in the aorta of diabetic rats 
than in SHR or obese Zucker rats. The increased transport of serum fructose (resulting from 
raised GLUT5 mRNA levels in aorta) and the high glucose-activated polyol pathway 
metabolism (indicated by the elevated levels of aldose reductase mRNA and sorbitol in the 
aorta) both account for the higher levels of cellular fructose, fructose-induced fructokinase, 
and aldolase B expression and MG in the aorta of these diabetic rats. Unchanged levels of 
G-6-P and down-regulated aldolase A expression by high glucose suggests a lesser 
contribution of glycolysis to aortic MG overproduction in diabetic rats.  
 
3.6 Acknowledgements  
We are grateful to Mrs. Arlene Drimmie (Department of Pharmacology, University of 
Saskatchewan) for her excellent technical assistance. This work was supported by operating 
grants from Canadian Institutes of Health Research and the Heart and Stroke Foundation of 
Saskatchewan to L. Wu. J. Liu was supported by College of Medicine Graduate Scholarship, 
University of Saskatchewan.  
 
74 
 
Table 3-1 Basal parameters in serum of rat models. 
Rat models 
Age 
(wks) 
n 
MG 
(μM) 
Fructose 
(mM) 
Glucose  
(mM) 
Insulin  
(ng/mL) 
WKY 20 4 1.2±0.04 0.27±0.06 5.3±0.1 3.5±0.2 
SHR 20 4 1.7±0.05** 0.46±0.04* 5.6±0.3 10.1±1.7** 
Lean Zucker 16 5 1.1±0.05 0.25±0.05 4.9±0.06 2.4±0.2 
Obese Zucker 16 5 1.4±0.04** 0.33±0.06 5.3±0.3 5.8±0.4** 
Diabetic 
Zucker 
16 5 2.3±0.1**
##
 0.53±0.05**
#
 19.2±0.6**
##
 1.1±0.1**
##
 
*
P<0.05, 
**
P<0.01 vs. WKY or lean Zucker rats; 
#
P< 0.05,
 ##
P< 0.01 vs. obese Zucker  
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Figure 3-1 Fructose, aldolase B and MG in aorta of fructose-induced or genetic 
hypertensive rats. (A) Levels of MG and fructose, and mRNA levels of (B) glucose 
transporter 5 (GLUT5), aldose reductase, (C) semicarbazide-sensitive amine oxidase (SSAO), 
cytochrome P450 2E1 (CYP 2E1), aldolase A, and aldolase B in the aorta of 20-week-old 
Sprague Dawley (SD) rats treated or untreated with 60% fructose for 16 weeks. (D) Levels of 
MG and fructose, and (E, F) mRNA levels of different genes in the aorta of 20-week-old 
spontaneously hypertensive rats (SHR) and control Wistar-Kyoto (WKY) rats. 
*
P<0.05, 
**
P<0.01 vs. un-treated SD or WKY rats. n = 4 for each group in A-F.  
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Figure 3-2 Fructose, aldolase B and MG in aorta of Zucker rats. (A) Levels of MG and 
fructose, (B) levels of glucose transporter 5 (GLUT5) and fructokinase mRNA, (C) levels of 
aldose reductase mRNA and sorbitol, and (D) levels of semicarbazide-sensitive amine 
oxidase (SSAO), cytochrome P450 2E1 (CYP 2E1), aldolase A, and aldolase B mRNA in the 
aorta of 16-week-old lean, obese, and diabetic Zucker rats. 
*
P<0.05, 
**
P<0.01 vs. lean rats 
and 
#
P< 0.05,
 ##
P< 0.01 vs. obese rats.  n = 5 for each group in A-D.  
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Figure 3-3 MG and fructose formation in A-10 cells. (A) Fructose or glucose (25 
mM)-induced MG formation in A-10 cells. (B) MG levels in cells co-treated with fructose 
and insulin (100 nM) for 6 and 12 h. (C) Time-dependent increases in fructose levels in cells 
treated with fructose, glucose, and/or insulin. (D) Activity of glyoxalase 1 or glyoxalase 2 in 
cells after 12- or 24-h treatment. *P<0.05, **P<0.01 vs. control (5 mM glucose) and 
#
P< 0.05,
 
##
P< 0.01 vs. without insulin. n = 5 for each group in A-C and n = 6 for each group in D.  
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Figure 3-4 Fructose, aldolase B and MG in A-10 cells treated with fructose and/or 
insulin. mRNA levels of (A) glucose transporter 5 (GLUT5), fructokinase, (B) aldolase A and 
aldolase B, and (C) protein levels of aldolase B in cells treated with fructose (25 mM) and/or 
insulin (100 nM) for 12 h, *P<0.05, **P<0.01 vs. control (5 mM glucose) and 
#
P< 0.05,
 ##
P< 
0.01 vs. without insulin. (D) Levels of aldolase B mRNA, protein (boxed inset) and MG in 
cells transfected with control or aldolase B shRNA, 
**
P<0.01 vs. control shRNA and 
##
P< 
0.01 vs. control (5 mM glucose). n = 5 for each group in A-D.  
79 
 
 
Figure 3-5 Fructose, aldolase B and MG in A-10 cells treated with glucose. (A) levels of 
glucose 6-phosphate (G-6-P), sorbitol, and GA3P + DHAP in cells treated with glucose for 12 
h. (B) Levels of MG, (C) mRNA and (D) protein levels of aldolase A or aldolase B in cells 
treated with glucose in the presence or absence of sorbinil (Sor, 10 μM) and CP-470711 (CP, 
1 μM) for 12 h, *P<0.05, **P<0.01 vs. 5 mM glucose, #P<0.05, ##P<0.01 vs. 25 mM glucose. 
(E) Levels of aldolase A mRNA, protein (boxed inset) and MG in cells transfected with 
different shRNA, 
*
P<0.05, 
**
P<0.01 vs. control shRNA and 
##
P< 0.01 vs. control (5 mM 
glucose). n = 5 for each group in A-E.  
80 
 
 
Figure 3-6 Summary of the mechanism for vascular MG overproduction in rat models 
with metabolic syndrome. Serum and aortic fructose levels are increased in fructose-fed SD, 
spontaneously hypertensive rats (SHR), and obesity rats, which up-regulate aldolase B 
expression and enhance MG generation in rat aorta. Hyperinsulinemia in these rats may 
promote aortic fructose accumulation and MG generation via up-regulating fructose 
transporter GLUT5. Hyperglycemia in diabetic rats down-regulates aldolase A, but activates 
polyol pathway and increases fructose generation in the aorta, leading to up-regulation of 
aldolase B and overproduction of MG. Moreover, serum fructose and aortic GLUT5 mRNA 
levels are increased in diabetic rats, indicating an important contribution of the elevated 
serum fructose to the MG overproduction.    
 
Abbreviations: DHAP – dihydroxyacetone phosphate; F-1-P – fructose 1-phosphate; F-1,6-P2 
– fructose 1,6-bisphosphate; G-6-P – glucose 6-phosphate; GA3P – glyceraldehyde 
3-phosphate; GLUT1, GLUT5 – glucose transporter 1 and 5, respectively; MG – 
methylglyoxal; SD – Sprague Dawley; WKY – Wistar-Kyoto.  
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3.7 Supplementary materials  
Table 3-S1. mRNA levels of fructokinase in the aorta of rat models. 
 
 
 
 
*
P<0.05, 
**
P<0.01 vs. Un-treated SD or WKY rats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rat models 
Age 
(wks) 
n Fructokinase mRNA (%) 
Un-treated SD 20 4 100±16 
Fru.-treated SD 20 4 191±23 * 
WKY 20 4 100±16 
SHR 20 4 208±12 ** 
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Figure 3-S1 Spontaneous MG production from GA3P or DHAP dissolved in PBS buffer, 
in the presence or absence of 3 U/mL triose phosphate isomerase (TIM), at 37°C in the 
Eppendorf tubes, 
*
P<0.05, 
**
P<0.01 vs. GA3P alone and 
#
P< 0.05,
 ##
P< 0.01 vs. DHAP alone. 
n = 5 for each group in A and B. Triose phosphate isomerase, an enzyme catalyzing the 
inter-conversion of GA3P and DHAP, was observed to change the conversion rate of each 
triose phosphate to MG but not to increase the total formation of MG. 
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Figure 3-S2 Cytochrome P450 2E1 (CYP 2E1), semicarbazide-sensitive amine oxidase 
(SSAO) and MG in A-10 cells. (A) MG levels in A-10 cells treated with 25 mM acetone, 
glycine, or threonine (glycine and threonine are precursors of aminoacetone) for different 
times. (B, C) MG levels in A-10 cells cultured in different treatments for 12 h in the presence 
or absence of diallyl disulfide (DADS, 100 μM, a CYP 2E1 inhibitor) or 
(E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974, 5 μM, a SSAO inhibitor) (n = 5 
for each group in A-C).  
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4.1 Abstract  
We used the cultured endothelial EA. hy926 cell as a model to examine whether 
up-regulation of aldolase B and enhanced MG formation play an important role in high 
glucose-induced overproduction of advanced glycation endproducts (AGEs), oxidative stress 
and cellular dysfunction. High glucose (25 mM) incubation of EA. hy926 cells increased 
mRNA levels of aldose reductase (an enzyme converting glucose to fructose) and aldolase B 
(a key enzyme that catalyzes MG formation from fructose) and enhanced MG formation. 
High glucose-induced cellular MG overproduction was completely prevented by siRNA 
knockdown of aldolase B, but unaffected by siRNA knockdown of aldolase A, an enzyme 
responsible for MG formation during glycolysis, and by inhibition of cytochrome P450 2E1 
and semicarbazide-sensitive amine oxidase, accounting for MG formation from metabolism 
of lipid and proteins, respectively. Both high glucose (25 mM) and MG (30, 100 μM) 
increased the formation of N(ε)-carboxyethyl-lysine (CEL, a MG-induced AGE), oxidative 
stress (determined by the generation of oxidized DCF, H2O2, protein carbonyls and 
8-oxo-dG), O-GlcNAc modification (product of hexosamine pathway), membrane protein 
kinase C activity and nuclear translocation of NF-κB in EA. hy926 cells. However, the above 
metabolic and signaling alterations induced by high glucose were completely prevented by 
knockdown of aldolase B and partially by application of aminoguanidine (a MG scavenger) 
or alagebrium (an AGEs breaker). In conclusion, efficient inhibition of aldolase B can 
prevent high glucose-induced overproduction of MG and related cellular dysfunction in 
endothelial cells. 
Key words: Aldolase B, Methylglyoxal, Glucose, Endothelial cell 
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4.2 Introduction 
Hyperglycemia damages blood vessels and induces diabetic vascular complications in 
the retinal, renal, and cardiovascular tissues (106, 269). Vascular endothelial cell is the early 
and primary target of hyperglycemic damage in diabetes (270, 271). It has been reported that 
hyperglycemia increased endothelial permeability and inflammation, decreased nitric oxide 
(NO) bioavailability and endothelium-dependent relaxation, and vascular remodeling, thus 
hyperglycemia-triggered endothelial dysfunction is considered a key event in the 
pathogenesis of vascular complications of diabetes (136).  
Methylglyoxal (MG) is a highly reactive metabolite of glucose (146, 272). Increased 
MG levels were observed in vascular endothelial cells cultured in high glucose-containing 
media and in the aorta, kidney and retina of diabetic rats (36, 70, 87). Accumulating evidence 
indicates that high glucose-increased MG production is an important molecular mechanism 
linking diabetes to endothelial damage. MG modifies lysine, arginine, and cysteine residues 
in peptides or proteins to yield irreversible advanced glycation end products (AGEs), leading 
to cross-linking and denaturation of proteins (37, 38, 132). MG also increases the generation 
of reactive oxygen species (ROS) and oxidative stress in endothelial cells (70). Studies on 
cultured vascular smooth muscle cells (VSMCs) showed that MG treatment induced the 
activation of NF-κB (56). Moreover, indirect evidence implicates MG in the high 
glucose-activated protein kinase C (PKC) and hexosamine pathway. For example, incubation 
with alagebrium, an AGEs breaker, reduced PKC activation in high glucose-treated VSMCs 
(123). Activation of hexosamine pathway by hyperglycemia leads to O-linked N-acetyl 
glucosamine (O-GlcNAc) modification of various proteins on serine or threonine residues 
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which impairs the normal functions of proteins (106). Overexpression of glyoxalase-1, an 
enzyme metabolizing MG, reduced high glucose-increased O-GlcNAc modification in 
endothelial cells (111). These data suggest that inhibition of MG production could be a 
strategy to prevent endothelial damage in diabetic vascular complications.  
Several MG scavengers have been developed, but most of them, such as 
aminoguanidine, metformin and N-acetyl cysteine, are non-specific to MG and their 
utilization for scavenging MG and preventing diabetic damage are limited (205). We recently 
identified aldolase B, which converts glucose or fructose to MG, but not aldolase A, 
cytochrome P450 2E1 (CYP 2E1), and semicarbazide-sensitive amine oxidase (SSAO), as a 
primary enzyme responsible for MG overproduction in high glucose-treated VSMCs and in 
the aorta of diabetic rats (272). In this paper, the gene expression of aldolase B and its role in 
MG formation in high glucose-treated endothelial cells were evaluated and whether 
knockdown of aldolase B in endothelial cells prevented high glucose-induced MG 
overproduction and other metabolic and signaling abnormities was investigated.  
 
4.3 Methods 
4.3.1 Cell culture and treatment 
EA. hy926 cells, a endothelial cell line derived from the fusion of human umbilical 
vein endothelial cells with A549 lung carcinoma cells (a gift kindly provided by Dr. 
Cora-Jean Edgell, University of North Carolina at Chapel Hill), were cultured in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). EA. 
hy926 cells were starved in DMEM containing 0.5% FBS for 24 h and then treated with 
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glucose (25 mM) or MG (30 or 100 μM) in DMEM containing 10% FBS for 3 days. Medium 
was not changed during the treatment. The control cells were EA. hy926 cells that were 
cultured in FBS (10%) - DMEM (5 mM glucose) without adding 25 mM glucose, MG or 
other agents into the medium.   
 
4.3.2 Small interfering RNA (siRNA) 
Knockdown of aldolase A or aldolase B was established by 24-h transfection of cells 
with a siRNA pool (a mixture of 3 or 4 different siRNA duplexes) targeting aldolase A or B 
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) in DharmaFECT™ 4 Transfection 
Reagent (Thermo Fisher, Nepean, ON, Canada). Briefly, transfection complexes were formed 
by incubating 100 μL siRNA pool (10 μM) with 25 μL of DharmaFECT 4 in 1 mL of 
serum-free DMEM for 20 min at room temperature. Transfection complexes were mixed with 
4 mL of serum-free DMEM and added to the medium. After 6 h of incubation, 5 mL DMEM 
supplemented with 20% FBS was added for a final siRNA concentration at 100 nM. After 
another 18 h, the transfection medium was replaced by 10% FBS DMEM with or without 
MG or high glucose and incubated for 3 days. Aldolase B mRNA was determined by a 
real-time PCR assay using SYBR Green PCR Master Mix (Bio-Rad) with the primers for 
human aldolase B (forward 5'-AGCCTCGCTATCCAGGAAAACG-3', reverse 
5'-TGGCAGTGTTC CAGGTCATGGT-3') and β-actin (forward 
5'-ACTTAGTTGCGTTACACCCTT-3', reverse 5'-GTCACCTTCACCGTTCCA-3').  
Primers for human aldolase A and aldose reductase were purchased from Qiagen 
(Mississauga, ON, Canada). 
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4.3.3 MG Measurement  
MG levels were determined using our recently modified method (251). Briefly, cells 
were sonicated three times for 5 seconds each time and centrifuged at 12,000 rpm (10 min, 
4°C). The supernatant of 180 μL was incubated with 180 μL of perchloric acid (PCA, 1 N) 
and 40 μL of o-phenylenediamine (o-PD, 100 mM) for 24 h at room temperature in the dark. 
The mixture was centrifuged at 12,000 rpm (10 min, 4°C). The supernatant of 180 μL was 
mixed with 20 μL of 5-methylquinoxaline (5-MQ, internal standard) and analyzed by 
high-performance liquid chromatography (HPLC) with a mobile phase buffer containing 17% 
acetonitrile, 8% 50 mM NaH2PO4 (pH 4.5), and 75% water.  
 
4.3.4 Confocal imaging of AGEs 
N(ε)-carboxyethyl-lysine (CEL) is a MG specific AGE formed by the reaction 
between MG and lysine residues in proteins (273). CEL formation in EA. hy926 cells was 
visualized by confocal microscopy after immunofluorescent staining. Cells were cultured on 
glass coverslips, fixed and permeabilized with pre-chilled methanol (20 min, -20°C), blocked 
with goat serum in phosphate-buffered saline (PBS) (1:30, 30 min), and then, incubated with 
mouse monoclonal CEL antibody (Cosmo Bio USA, Inc., Carlsbad, CA, USA, diluted 1:250 
in blocking solution, 3 h at room temperature or overnight at 4°C). Subsequently, the 
processed cell preparations were washed with PBS, and incubated with Alexa 488-conjugated 
secondary antibodies (Invitrogen, Burlington, ON, Canada, diluted 1:300 in blocking solution, 
2 h at room temperature). Finally, the prepared cells were washed again and mounted in 
mounting media with propidium iodide (Invitrogen, Burlington, ON, Canada). Thereafter, the 
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slides were examined under a confocal microscope with the appropriate filters. The 
fluorescence intensity was determined using Image J by analyzing at least 50 random cells 
per sample. 
 
4.3.5 Measurement of oxidative stress  
After different treatments, cells were washed with PBS, and then stained with a 
non-specific ROS probe (DCF-DA, Invitrogen, Burlington, ON, Canada) or a specific 
fluorogenic H2O2 probe (Calbiochem, San Diego, CA, USA). The fluorescence intensities of 
these probes were analyzed with a Fluoroskan Ascent plate reader (Thermo LabSystem, 
Franklin, MA, USA) as previously described (55, 254). Protein oxidation was assessed by 
measuring total protein carbonyls with an immunoblot kit (Cell Biolabs Inc., San Diego, CA, 
USA). DNA oxidation biomarker 8-oxo-dG was visualized by immunofluorescent staining 
and photographed under fluorescence microscopy, using a specific mouse monoclonal 
8-oxo-dG antibody (Trevigen, Gaithersburg, MD, USA), following the manufacturer's 
instructions. 
 
4.3.6 Western blot analysis  
Cells were harvested and lysed in RIPA buffer (Santa Cruz Biotechnology Inc., Santa 
Cruz, CA, USA) supplemented with protease inhibitors. Total cellular proteins were 
fractionated by 10% SDS-PAGE and immunoblotted with antibodies as follows: O-GlcNAc 
(RL2) (1:1000, Thermo Fisher, Nepean, ON, Canada), and α-tubulin (1:500, Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA). Nuclear proteins were extracted as previously 
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described (255) and level of nuclear NF-κB was measured with antibodies against NF-κB 
(p65) (1:500) and lamin B (1:1000) purchased from Santa Cruz Biotechnology Inc., Santa 
Cruz, CA, USA.   
 
4.3.7 Membrane PKC activity  
Cells cultured on 100-mm dish were washed, scrapped off, suspended in 1 mL of 
Tris-sucrose buffer (20 mM Tris-base, 2 mM EDTA, 0.5 mM EGTA and 0.3 M sucrose, pH 
7.4), and then added with protease inhibitors and homogenized by being passed 15 times 
through a 27.5 gauge needle. After centrifugation at 2,500 g (10 min, 4°C) to remove nuclei 
and cell debris, cell membrane was fractionated by high speed ultra-centrifugation at 105,000 
g (30 min, 4°C). Membrane pellets were washed with Tris buffer (20 mM Tris-base, 2 mM 
EDTA and 0.5 mM EGTA, pH 7.4), ultra-centrifuged (105,000 g, 30 min, 4°C) and 
re-suspended in 0.3 mL of Tris buffer with 0.5% Triton X-100 on ice for 1 h. The supernatant 
after ultra-centrifugation (105,000 g, 30 min, 4°C) was collected and membrane PKC 
proteins were purified through a DEAE cellulose (DE-52) column previously equilibrated 
with the Tris buffer. After washing the column with 3 mL of Tris buffer, the bound PKC was 
eluted with 0.5 ml Tris buffer containing 0.2 M NaCl. Membrane PKC activity was assessed 
by a PKC activity assay kit according to the manufacturer's instructions (Assay Designs, Ann 
Arbor, MI, USA).  
 
4.3.8 Materials 
(E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974) was a generous gift from 
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Dr. Peter Yu (Department of Pharmacology, University of Saskatchewan, Canada). 
Alagebrium was a generous gift from Synvista Therapeutics (Montvale, NJ). Diallyl disulfide 
(DADS) and aminoguanidine were purchased from Sigma-Aldrich, Oakville, ON, Canada 
 
4.3.9 Statistics 
Data are expressed as mean ± SEM from at least five independent experiments (n≥5 
in each group). Statistical analyses were performed using parametric Student's t-test 
(two-tailed) or one-way ANOVA followed by posthoc Tukey's test. 
 
4.4 Results   
4.4.1 Knockdown of aldolase B prevented high glucose-increased MG formation   
High glucose (25 mM) treatment up-regulated aldose reductase and aldolase B mRNA 
expression and accelerated MG formation in endothelial EA. hy926 cells (Figure 4-1A). 
Cellular MG overproduction induced by high glucose was partially reduced by 
aminoguanidine, and not reduced by alagebrium (Figure 4-1B). Transfection with aldolase B 
siRNA reduced cellular mRNA levels of aldolase B by 74%, and completely prevented high 
glucose-elevated formation of MG in endothelial cells (Figures 4-1C, 4-1D). Aldolase A, 
cytochrome P450 2E1 (CYP 2E1) and semicarbazide-sensitive amine oxidase (SSAO) are 
responsible for MG generation in glycolysis and in the metabolism of fatty acids and proteins, 
respectively (272). However, high glucose-increased cellular MG production was not affected 
by application of DADS (an inhibitor of CYP 2E1) or MDL-72974 (an inhibitor of SSAO), or 
by transfection with aldolase A siRNA which reduced cellular mRNA levels of aldolase A by 
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70% (Figures 4-1E, 4-1F and 4-1G). 
 
4.4.2 Knockdown of aldolase B prevented high glucose-increased AGEs formation 
Since incubation of EA. hy926 cells with MG (100 μM) or glucose (25 mM) induced 
a similar increase in cellular MG levels (Figure 4-2A), the direct effects of MG (30 or 100 
μM) on endothelial cells were investigated. MG (30 or 100 μM) elevated CEL levels in EA. 
hy926 cells (Figure 4-2B). Glucose (25 mM) treatment increased cellular CEL levels, which 
was similar with that induced by MG (100 μM) (Figures 4-2B, 4-3C). High glucose-induced 
CEL overproduction in endothelial cells was partially reduced by aminoguanidine, but was 
completely reversed or prevented by alagebrium or knockdown of aldolase B (Figures 4-2C, 
4-2D).   
 
4.4.3 Knockdown of aldolase B prevented high glucose-induced ROS 
High glucose-increased production of ROS is regarded as an important contributor to 
endothelial dysfunction in diabetic vascular complications (274). MG (30 or 100 μM,) 
elevated levels of oxidized DCF (an indicator of total cellular ROS) in EA. hy926 cells 
(Figure 4-3A). The increase in oxidized DCF levels induced by MG (100 µM) was similar 
with that induced by glucose (25 mM) (Figures 4-3A, 4-3B). High glucose-increased cellular 
formation of oxidized DCF was totally abolished by aminoguanidine or by transfection with 
aldolase B siRNA, and partially reduced by alagebrium (Figures 4-3B, 4-3C). Cellular levels 
of H2O2 were similarly elevated by MG (100 μM) and glucose (25 mM) (Figures 4-4A, 4-4B). 
Application of aminoguanidine or alagebrium, or transfection of aldolase B siRNA prevented 
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the formation of H2O2 in high glucose-treated endothelial cells (Figures 4-4B, 4-4C).   
 
4.4.4 Knockdown of aldolase B prevented high glucose-induced protein and DNA 
oxidation  
MG (100 μM) and glucose (25 mM) induced similar increases in levels of protein 
carbonyls (a marker of protein oxidation) in EA. hy926 cells (Figures 4-5A, 4-5B). 
Application of aminoguanidine or transfection of aldolase B siRNA totally abolished high 
glucose-increased levels of protein carbonyls (Figures 4-5B, 4-5C). Application of 
alagebrium partially reduced the formation of protein carbonyls in high glucose-treated cells 
(Figures 4-5B, 4-5C).   
MG (30 or 100 μM, 3 days) elevated levels of 8-oxo-dG (a marker of DNA oxidation) 
in EA. hy926 cells (Figures 4-6A). The increase of 8-oxo-dG levels induced by MG (100 µM) 
was similar to that induced by glucose (25 mM) (Figures 4-6A, 4-6B). High 
glucose-increased 8-oxo-dG levels were prevented by aminoguanidine or by transfection with 
aldolase B siRNA, and partially reduced by alagebrium (Figures 4-6B, 4-6C). 
 
4.4.5 Knockdown of aldolase B blocked high glucose-activated metabolic or signalling 
pathways  
Activation of hexosamine pathway by high glucose causes an elevated O-GlcNAc 
modification of nuclear and cytosolic proteins (106). MG (30 or 100 μM) increased 
O-GlcNAc modification of proteins in EA. hy926 cells (Figure 4-7A). Glucose (25 
mM)-elevated O-GlcNAc modification was similar to that induced by MG (100 µM), and 
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totally abolished by alagebrium or by transfection with aldolase B siRNA but only partially 
reversed by aminoguanidine (Figures 4-7B, 4-7C).  
Activation of PKC leads to its translocation to the plasma membrane where it 
catalyzes the phosphorylation of various substrates and mediates a diverse variety of 
biological processes (114). MG (30 or 100 μM) elevated plasma membrane PKC activities in 
EA. hy926 cells (Figure 4-8A). High glucose (25 mM) incubation induced a similar elevation 
in the plasma membrane PKC activities as did 100 μM MG (Figures 4-8A, 4-8B). High 
glucose-elevated plasma membrane PKC activity was prevented by alagebrium or by 
knockdown of aldolase B, but only partially by aminoguanidine (Figures 4-8B, 4-8C). 
Activated NF-κB (p50/p65 dimer) is translocated into the nucleus and regulates the 
expression of a large number of genes involved in immune and inflammatory responses, 
apoptosis, cell proliferation and differentiation (125). It was reported that MG or glucose 
triggered the nuclear translocation of NF-κB but unchanged its total protein levels in cells (56, 
275, 276). Consistently, we found that MG (100 μM) and high glucose (25 mM) similarly 
increased nuclear p65 subunit of NF-κB in EA. hy926 cells (Figure 4-9A). High 
glucose-elevated nuclear amount of NF-κB p65 was blocked by alagebrium, aminoguanidine, 
and aldolase B knockdown (Figures 4-9B, 4-9C).    
 
4.5 Discussion 
Our present work demonstrated that siRNA knockdown of aldolase B blocked high 
glucose-activated metabolic and signaling pathways by the normalization of MG production 
in endothelial cells. This revelation was substantiated by the following observations: 1) 
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Treatment of EA. hy926 cells with MG (100 μM) and high glucose (25 mM) induced a 
similar increase in cellular MG levels and a similar activation of the major pathways involved 
in hyperglycemic damage; 2) Aldolase B is the major enzyme for high glucose-increased MG 
production in endothelial cells because aldolase B knockdown completely inhibited MG 
overproduction in high glucose-treated EA. hy926 cells; 3) Both knockdown of aldolase B 
and the application of aminoguanidine or alagebrium prevented high glucose-activated 
metabolic and signaling pathways in EA. hy926 cells.  
Enhanced accumulation of MG is postulated to be one of the important molecular 
mechanisms leading to endothelial dysfunction and diabetic vascular complications (70, 106, 
136). Our lab previously reported that incubation with MG (30 or 100 μM) and glucose (25 
mM) similarly decreased NO synthase activity and NO production in cultured endothelial 
cells and reduced endothelium-dependent muscle relaxation in the rat aorta (70). Our present 
study further validates the role of MG as an upstream activator for hyperglycemia-induced 
metabolic and signaling changes. MG is the major precursor of AGEs in endothelial cells (36). 
MG treatment elevated AGEs (as estimated by intracellular CEL) levels in EA. hy926 cells 
(Figure 4-2). AGEs alter protein structures and functions. For example, MG-modified 
extracellular matrix molecules impaired matrix-matrix interactions and increased the stiffness 
of the vasculature (42). In addition, AGEs can activate their specific receptors on endothelial 
cells and cause cellular perturbation, such as increased permeability, oxidative stress, 
activation of NF-κB and vascular inflammation (42, 49). MG is also a pro-oxidant (54, 55). A 
possible reason is a MG-induced decrease in mitochondrial complex III and SOD activities 
(66). Here we found MG enhanced the formation of ROS and oxidation of protein and DNA 
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in EA. hy926 cells (Figures 4-3, 4-4, 4-5, and 4-6). Moreover, we provide the first evidence 
that treatment with MG can directly stimulate O-GlcNAc modification and plasma membrane 
PKC activation (Figures 4-7, 4-8). It is well known that abnormal activation of PKC by high 
glucose decreased NO production and increased vasoconstrictor endothelin-1 (ET-1) and 
ROS production in endothelial cells (106). Increased O-GlcNAc modification of proteins 
appears to be important in the pathogenesis of endothelial dysfunction. For example, high 
glucose-increased O-GlcNAc modification of endothelial NO synthase decreased its activity 
in endothelial cells (108). We also found that MG directly activated NF-κB by stimulating its 
nuclear translocation in endothelial cells (Figure 4-9). High glucose-activated NF-κB via 
AGEs, ROS or PKC increased expression of genes contributing to endothelial dysfunction, 
such as ET-1, adhesion molecules and inflammatory cytokines (42, 97, 124) .  
Aldolase B is a major enzyme responsible for high glucose-induced MG 
overproduction in VSMCs and the aorta (272). GA3P and DHAP, which are produced by 
aldolase A or aldolase B during glucose metabolism, are considered major sources for 
endogenous MG formation and showed high efficiencies of non-enzymatic conversion to MG 
(5, 6, 272). Secondary sources of MG include the oxidation of aminoacetone by SSAO and 
the oxidation of acetone by CYP 2E1 (59). We have recently reported that aldolase B, but not 
aldolase A, SSAO or CYP 2E1, was up-regulated and MG was over-produced in the aorta of 
diabetic rats; knockdown of aldolase B prevented high glucose-elevated MG formation in 
VSMCs (272). In the present work, we observed that high glucose up-regulated aldolase B 
expression and increased MG formation in endothelial cells. siRNA knockdown of aldolase B 
completely inhibited the excess MG generation in glucose-treated endothelial cells (Figure 
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4-1). However, siRNA knockdown of aldolase A or inhibition of SSAO or CYP 2E1 had no 
effect on glucose-increased cellular MG overproduction (Figure 4-1). These data indicate that 
aldolase B is predominantly responsible for glucose-increased MG formation in endothelial 
cells and the inhibition of MG formation is solely responsible for the observed effects of 
aldolase B knockdown on high glucose-activated metabolic and signaling pathways.   
Aminoguanidine and alagebrium are the most widely used MG scavenger and AGEs 
breaker, respectively (205). The inhibitory effects of aminoguanidine or alagebrium on high 
glucose-induced endothelial abnormalities confirm the role of MG as a mediator of high 
glucose-activated cellular pathways (Figures 4-2 - 4-9). However, our work also reveals 
limitations of aminoguanidine or alagebrium in accurately evaluating MG’s contribution to 
endothelial dysfunction and diabetic complications, when compared with the knockdown of 
aldolase B which specifically prevents glucose-induced MG overproduction. Aminoguanidine 
is a non-specific MG scavenger. Its guanidine residue can react with the carbonyl in MG or in 
other carbonyl compounds, such as 3-deoxyglucosone and malondialdehyde (205). Moreover, 
aminoguanidine can react directly with ROS, such as H2O2, hydroxyl radical and 
peroxynitrite (220). We found that the application of aminoguanidine completely abolished 
oxidative stress, but only partially decreased MG and CEL production, O-GlcNAc 
modification and plasma membrane PKC activities in high glucose-treated cells (Figures 4-1 
- 4-8). Alagebrium breaks the established AGE crosslinks (205). The application of 
alagebrium completely inhibited the formation of CEL, but it did not change MG levels in 
high glucose-treated EA. hy926 cells (Figures 4-1, 4-2). In addition to the formation of AGEs, 
MG also stimulates the formation of ROS (66). Our studies showed that alagebrium only 
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partially reduced the formation of oxidized DCF, protein carbonyls and 8-oxo-dG in high 
glucose-treated EA. hy926 cells (Figures 4-3, 4-5, and 4-6), although it can react with H2O2 
in the test tube (277), and completely reduced the glucose-increased H2O2 formation in our 
test cells (Figure 4-4).   
In conclusion, MG directly mediates high glucose-induced production of AGEs, 
oxidative stress, and increases in O-GlcNAc modification and protein levels or activities of 
protein kinase C and NF-κB in endothelial cells. More importantly, this study demonstrates 
that aldolase B is the major enzyme for glucose-increased MG production in endothelial cells. 
Knockdown of aldolase B prevents MG overproduction and, by doing so, blocks high 
glucose-induced activation of multiple metabolic and signaling pathways in endothelial cells.  
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Figure 4-1 Knockdown of aldolase B prevented MG overproduction in high 
glucose-treated EA. hy926 cells. (A) Real-time PCR analysis of aldose reductase (AR) and 
aldolase B expression in cells treated with glucose (Glu) for 3 days. 
**
P<0.01 vs. 5 mM 
glucose; (B) MG levels in cells treated with glucose in the presence or absence of 
aminoguanidine (AG, 1 mM) and alagebrium (ALA, 100 μM) for 3 days. **P<0.01 vs. 5 mM 
glucose;
 ##
P<0.01 vs. 25 mM glucose. (C) Levels of aldolase B mRNA and (D) levels of MG 
in wide-type cells (WT) and cells transfected with control or aldolase B siRNA, or only 
transfection agent (Mock).  
**
P<0.01 vs. 5 mM glucose;
 ##
P<0.01 vs. control siRNA. (E) 
MG levels in cells treated with 25 mM glucose in the presence or absence of 
(E)-2-(4-fluorophenethyl)-3- fluoroallylamine (MDL-72974, 5 μM) or diallyl disulfide 
(DADS, 100 μM) for 3 days. (F) Levels of aldolase A mRNA and (G) levels of MG in cells 
transfected with control or aldolase A siRNA. 
##
P<0.01 vs. control siRNA. 
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Figure 4-2 Knockdown of aldolase B prevented AGEs overproduction in high 
glucose-treated EA. hy926 cells. Levels of MG (A) and N(ε)-carboxyethyl-lysine (CEL) in 
green (B) in cells treated with exogenous MG for 3 days. 
**
P<0.01 vs. control (5 mM 
glucose). (C) CEL levels in cells treated with glucose (Glu) in the presence or absence of 
aminoguanidine (AG, 1 mM) and alagebrium (ALA, 100 μM) for 3 days. **P<0.01 vs. 5 mM 
glucose;
 ##
P<0.01 vs. 25 mM glucose. (D) CEL levels in cells transfected with control or 
aldolase B siRNA, or only transfection agent (mock). 
**
P<0.01 vs. 5 mM glucose; 
##
P<0.01 
vs. control siRNA. Nuclear DNA (red) was stained with propidium iodide. The summary of 
fluorescence intensity of CEL was measured using Image J by analyzing at least 50 random 
cells in each group. 
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Figure 4-3 Knockdown of aldolase B prevented the increase of oxidized DCF levels in 
high glucose-treated EA. hy926 cells. (A) Levels of oxidized DCF in cells treated with 
exogenous MG for 3 days. 
**
P<0.01 vs. control (5 mM glucose). (B) Levels of oxidized DCF 
in cells treated with glucose (Glu) in the presence or absence of aminoguanidine (AG, 1 mM) 
and alagebrium (ALA, 100 μM). *P<0.05, **P<0.01 vs. 5 mM glucose; ##P<0.01 vs. 25 mM 
glucose. (C) Levels of oxidized DCF in cells transfected with control or aldolase B siRNA, or 
only transfection agent (mock). 
**
P<0.01 vs. 5 mM glucose; 
##
P<0.01 vs. control siRNA.  
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Figure 4-4 Knockdown of aldolase B prevented the generation of H2O2 in high 
glucose-treated EA. hy926 cells. (A) Levels of H2O2 in cells treated with exogenous MG for 
3 days. 
**
P<0.01 vs. control (5 mM glucose). (B) Levels of H2O2 in cells treated with glucose 
(Glu) in the presence or absence of aminoguanidine (AG, 1 mM) and alagebrium (ALA, 100 
μM). *P<0.05, **P<0.01 vs. 5 mM glucose; ##P<0.01 vs. 25 mM glucose. (C) Levels of H2O2 
in cells transfected with control or aldolase B siRNA, or only transfection agent (mock). 
**
P<0.01 vs. 5 mM glucose; 
##
P<0.01 vs. control siRNA.  
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Figure 4-5 Knockdown of aldolase B prevented protein oxidation in high glucose-treated 
EA. hy926 cells. (A) Levels of protein carbonyls in cells treated with exogenous MG for 3 
days. 
**
P<0.01 vs. control (5 mM glucose). (B) Levels of protein carbonyls in cells treated 
with glucose (Glu) in the presence or absence of aminoguanidine (AG, 1 mM) and 
alagebrium (ALA, 100 μM). *P<0.05, **P<0.01 vs. 5 mM glucose; ##P<0.01 vs. 25 mM 
glucose. (C) Levels of protein carbonyls in cells transfected with control or aldolase B siRNA, 
or only transfection agent (mock). 
**
P<0.01 vs. 5 mM glucose; 
##
P<0.01 vs. control siRNA.  
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Figure 4-6 Knockdown of aldolase B prevented DNA oxidation in high glucose-treated 
EA. hy926 cells. (A) Levels of 8-oxo-dG in cells treated with exogenous MG for 3 days. 
**
P<0.01 vs. control (5 mM glucose). (B) Levels of 8-oxo-dG in cells treated with glucose 
(Glu) in the presence or absence of aminoguanidine (AG, 1 mM) and alagebrium (ALA, 100 
μM). *P<0.05, **P<0.01 vs. 5 mM glucose; ##P<0.01 vs. 25 mM glucose. (C) Levels of 
8-oxo-dG in cells transfected with control or aldolase B siRNA, or only transfection agent 
(mock). 
**
P<0.01 vs. 5 mM glucose; 
##
P<0.01 vs. control siRNA. The summary o f 
fluorescence intensity of 8-oxo-dG was measured using Image J by analyzing at least 50 
random cells in each group. 
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Figure 4-7 Knockdown of aldolase B prevented high glucose-increased O-GlcNAc 
modification in EA. hy926 cells. (A) O-GlcNAc modification of total cellular proteins in 
cells treated with exogenous MG for 3 days. 
**
P<0.01 vs. control (5 mM glucose). (B) 
O-GlcNAc modification of total cellular proteins in cells treated with glucose (Glu) in the 
presence or absence of aminoguanidine (AG, 1 mM) and alagebrium (ALA, 100 μM). 
*
P<0.05, 
**
P<0.01 vs. 5 mM glucose;
 ##
P<0.01 vs. 25 mM glucose. (C) O-GlcNAc 
modification of total cellular proteins in cells transfected with control or aldolase B siRNA, 
or only transfection agent (mock). 
**
P<0.01 vs. 5 mM glucose; 
##
P<0.01 vs. control siRNA.  
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Figure 4-8 Knockdown of aldolase B prevented high glucose-increased membrane PKC 
activities in EA. hy926 cells. (A) Membrane PKC activities in cells treated with exogenous 
MG for 3 days. 
**
P<0.01 vs. control (5 mM glucose). (B) Membrane PKC activities in cells 
treated with glucose (Glu) in the presence or absence of aminoguanidine (AG, 1 mM) and 
alagebrium (ALA, 100 μM). *P<0.05, **P<0.01 vs. 5 mM glucose; ##P<0.01 vs. 25 mM 
glucose. (C) Membrane PKC activities in cells transfected with control or aldolase B siRNA, 
or only transfection agent (mock). 
**
P<0.01 vs. 5 mM glucose; 
##
P<0.01 vs. control siRNA.  
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Figure 4-9 Knockdown of aldolase B prevented high glucose-increased NF-κB nuclear 
translocation in EA. hy926 cells. (A) Nuclear p65 subunit of NF-κB in cells treated with 
exogenous MG for 3 days. 
**
P<0.01 vs. control (5 mM glucose). (B) Nuclear p65 subunit of 
NF-κB in cells treated with glucose (Glu) in the presence or absence of aminoguanidine (AG, 
1 mM) and alagebrium (ALA, 100 μM). **P<0.01 vs. 5 mM glucose; ##P<0.01 vs. 25 mM 
glucose. (C) Nuclear p65 subunit of NF-κB in cells transfected with control or aldolase B 
siRNA, or only transfection agent (mock). 
**
P<0.01 vs. 5 mM glucose; 
##
P<0.01 vs. control 
siRNA.  
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5.1 Abstract  
We previously reported that up-regulation of aldolase B, a key enzyme in fructose 
metabolism, is mainly responsible for vascular methylglyoxal (MG) overproduction under 
different pathological conditions. Here we report that in insulin-sensitive adipocytes it is 
aldolase A, an enzyme of the glycolytic pathway, which causes MG overproduction. In 
cultured 3T3-L1 adipocytes, glucose (25 mM) had no effect on aldolase A gene expression, 
but insulin (100 nM) up-regulated aldolase A mRNA and protein levels in the absence or 
presence of 25 mM glucose. Treatment with insulin (100 nM) increased the levels of basal 
MG or glucose (25 mM)-induced MG and glucose 6-phosphate. However, insulin (100 nM), 
glucose (25 mM), or their combination had no effect on cellular levels of sorbitol and 
fructose, but down-regulated gene expression of aldolase B to a similar extent, when 
compared with the control group. Incubation of 3T3-L1 adipocytes with fructose, acetone, 
acetol, threonine or glycine (25 mM) in the absence or presence of insulin (100 nM) did not 
alter cellular MG levels. The elevated MG levels induced by insulin (100 nM), glucose (25 
mM), or their combination in adipocytes was completely reduced by siRNA knockdown of 
aldolase A or application of 2-deoxy-D-glucose (a non-specific inhibitor of glucose uptake 
and glycolysis), but not by knockdown of aldolase B or by inhibition of aldose reductase, 
semicarbazide-sensitive amine oxidase or cytochrome P450 2E1. Our data indicate that 
insulin enhances MG overproduction in insulin-sensitive adipocytes by up-regulating 
aldolase A.  
Key words: aldolase A, methylglyoxal, glucose, insulin, adipocytes 
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5.2 Introduction 
Methylglyoxal (MG) is a highly reactive metabolite produced in mammalian cells. 
Glucose metabolites glyceraldehyde 3-phosphate (GA3P) and dihydroxyacetone phosphate 
(DHAP), which spontaneously and non-enzymatically degrade to MG, are considered major 
sources for endogenous MG formation (6, 258, 272). In the cytosol, glucose is 
physiologically metabolized through the glycolytic pathway into fructose 1,6-bisphosphate 
(F-1,6-P2), which subsequently forms GA3P and DHAP catalyzed by aldolase A (7). Glucose 
can also metabolize through the aldose reductase pathway into sorbitol by aldose reductase 
and then to fructose by sorbitol dehydrogenase (278). In some cell types, such as vascular 
smooth muscle cells (VSMCs), the aldose reductase pathway becomes active when 
intracellular glucose is elevated (272, 278, 279). Fructose is phosphorylated to fructose 
1-phosphate (F-1-P), which is cleaved by aldolase B to generate glyceraldehyde and DHAP 
(7). Secondary sources for MG formation include the degradation of aminoacetone generated 
from protein catabolism and ketone bodies (mainly acetone) from lipolysis by the action of 
semicarbazide-sensitive amine oxidase (SSAO) and cytochrome P450 2E1 (CYP 2E1), 
respectively (11, 280).  
The occurrence of high levels of glucose coupled with the accumulation of 
endogenous MG has received much attention in diabetes research due to the potentially 
pathogenic roles of MG and MG-induced advanced glycation endproducts (AGEs) in the 
development of diabetes and diabetic complications (106). Glucose enters insulin-insensitive 
VSMCs and endothelial cells (ECs) mainly through an insulin-independent glucose 
transporter 1 (GLUT1) (145, 281). Higher MG levels were observed in VSMCs and ECs 
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treated with high glucose and in the aorta, kidney and retina of diabetic rats (36, 70, 87, 272). 
We have identified aldolase B, but not aldolase A, as a key enzyme responsible for high 
fructose and glucose-induced MG overproduction in VSMCs (272). Fructose up-regulates 
aldolase B expression while high glucose is converted into fructose, which results in MG 
overproduction in VSMCs (272). Recently, MG formation in insulin-sensitive cells has 
received much attention since high levels of MG have been found to disturb insulin signaling 
in 3T3-L1 adipocytes (147) and skeletal muscle L6 cells (31). Moreover, MG modifies the 
insulin molecule and impairs its biological functions, such as insulin-stimulated glucose 
transport in adipocytes (37). However, whether MG is over-produced in the insulin-sensitive 
cells under different pathological conditions is unknown. GLUT1 is expressed in adipocytes, 
but its intrinsic activity is >90% suppressed (282). An insulin-responsive GLUT4 is highly 
expressed in adipocytes but under conditions of low insulin, is sequestered in intracellular 
vesicles (145). Hyperinsulinemia is commonly observed in hypertension, obesity, and the 
early stage of type 2 diabetes (272, 283, 284). High levels of insulin promote membrane 
translocation of GLUT4 and stimulate glucose transport in adipocytes (148). Treatment with 
insulin (100 nM) elevated basal glucose levels in adipose cells by 3.6-fold (187). Insulin can 
also enhance glycolysis via up-regulating the transcription of glycolytic enzymes, such as 
hexokinase II, phosphofructokinase, and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (149, 150). We hypothesize that insulin up-regulates aldolase A expression and 
enhances glucose-induced MG formation in adipocytes.    
In this study, cultured 3T3-L1 adipocytes were treated with insulin (100 nM), glucose 
(25 mM) or their combination. The relative contributions of different enzymes and pathways 
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to MG formation were evaluated by examining the gene expression of aldolase A and 
aldolase B and the glucose metabolism through glycolysis and the aldose reductase pathway, 
and by applying inhibitors for glycolysis, aldose reductase, SSAO, and CYP 2E1 as well as 
siRNA targeting aldolase A or B.  
 
5.3 Methods  
5.3.1 Cell culture 
Mouse 3T3-L1 fibroblasts were cultured in Dulbecco's Modified Eagle Medium 
(DMEM, 25 mM glucose) containing 10% fetal bovine serum (FBS) and 
penicillin-streptomycin (1% v/v) at 37°C in a humidified atmosphere of 5% CO2 and 95% air. 
3T3-L1 fibroblasts were differentiated into adipocytes in 100-mm culture dishes, as described 
previously (248). Two days after confluence, differentiation was initiated by incubation of 
cells for 3 days with DMEM (25 mM glucose, 10% FBS) supplemented with 0.25 µM 
dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine, and 172 nM insulin. The 
differentiation medium was changed every day. Thereafter, cells were grown in DMEM (25 
mM glucose, 10% FBS) containing 172 nM insulin for 2 days and then in DMEM (25 mM 
glucose, 10% FBS) without insulin till >90% of cells differentiated into adipocytes. The 
insulin sensitivity of adipocytes was confirmed by measuring insulin (100 nM, 30 
min)-stimulated uptake of [
3
H]2-deoxy-D-glucose (data not shown). Adipocytes were starved 
in FBS-free DMEM (5 mM glucose) for 24 h before treatments. The untreated or control cells 
were 3T3 cells that were cultured in FBS (10%) - DMEM (5 mM glucose) without adding 
agents such as 100 nM insulin or 25 mM glucose into medium.   
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5.3.2 Small interference RNA (siRNA) knockdown  
Knockdown of aldolase A or B was established by transfection of adipocytes with a 
siRNA pool (a mixture of 3 or 4 different siRNA duplexes) targeting aldolase A or B (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA, USA) in siRNA Transfection Reagent (Santa Cruz). 
Briefly, transfection complexes were formed by incubating 30 μL siRNA pool (10 μM) with 
30 μL of transfection reagent in 5 mL siRNA transfection medium (Santa Cruz) for 45 min at 
room temperature. Transfection complexes were added to cells grown in a 10-cm dish. After 
6 h of incubation, 5 mL DMEM supplemented with 20% FBS was added for a final siRNA 
concentration at 30 nM and incubated for 18 h. After that, cells were starved in FBS-free 
DMEM (5 mM glucose) for 24 h and then treated with 10% FBS DMEM in the presence or 
absence of insulin or/and glucose for 12 h. >90% cells are viable at 60 h after transfection. 
Gene knockdown was verified by Semi-Quantitative Nested RT-PCR with primers designed 
by Santa Cruz according to manufacturer's instructions.  
 
5.3.3 Biochemical assays 
Cell were sonicated and centrifuged at 12,000 rpm (10 min, 4°C). Total protein levels 
were determined with a bicinchoninic acid protein assay kit (Sigma-Aldrich, Oakville, ON, 
Canada). Intracellular fructose levels were measured by a fructose assay kit (BioVision, 
Mountain View, USA). Aliquots of supernatants were deproteinized by ¼ volume of 
perchloric acid (PCA, 1N) and neutralized by 2.5 M K2CO3 to measure the levels of glucose 
6-phosphate and sorbitol using the enzymatic fluorometric methods (272).  
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5.3.4 MG Measurement  
MG levels in 3T3-L1 adipocytes were determined with an o-phenylenediamine 
(o-PD)-based assay (56, 131, 132). Briefly, cells were sonicated (three times for 5 seconds 
each) and centrifuged at 12,000 rpm (10 min, 4°C). 240 μL of supernatant was mixed with 60 
μL of PCA (1 N), kept on ice for 10 min, and deproteinized by centrifuging at 12,000 rpm (10 
min, 4°C). Then 180 μL of supernatant was incubated with 90 μL of o-PD (100 mM) for 3 h 
at room temperature in the dark. The mixture was centrifuged at 12,000 rpm (5 min, 4°C). A 
portion of the supernatant (180 μL) was mixed with 20 μL of 5-methylquinoxaline (5-MQ, 
internal standard) and analyzed by high-performance liquid chromatography (HPLC) with a 
mobile phase buffer containing 17% acetonitrile, 8% 50 mM NaH2PO4 (pH 4.5), and 75% 
water.  
 
5.3.5 MG production in digitonin-permeabilized adipocytes    
Adipocytes were permeabilized with digitonin as previously described (285). Cells 
were harvested by trypsin digestion, washed with phosphate buffered saline (PBS), and then 
incubated in PBS containing 40 μg/ml digitonin for 5 min. After centrifugation at 1,000 rpm 
for 5 min, the cell pellets were washed twice with buffer A (150 mM sucrose, 35 mM 
potassium acetate, 35 mM KCl, 5 mM MgSO4, 5 mM NaH2PO4, and 40 mM Hepes, pH 7.55). 
Cell pellets were incubated at 37°C for 3 h in buffer A supplemented with 2 mM ATP, 1 mM 
NAD
+
 and different glucose metabolites. After centrifugation at 1,000 rpm for 5 min, the 
supernatant was collected for MG measurement.  
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5.3.6 Analysis of gene expression 
Total RNA was isolated using an RNeasy Mini Kit (Qiagen Inc., Mississauga, ON, 
Canada) and converted to cDNA with an iScript™ cDNA Synthesis Kit (Bio-rad, 
Mississauga, ON, Canada). Real-time PCR was performed using SYBR Green PCR Master 
Mix (Bio-rad, Mississauga, ON, Canada) with the following primers: mouse aldolase A 
forward 5'-CAACGGTCACAGCACTTC-3', reverse 5'-CTTCCTCACTCTGCCCTC-3'; 
mouse aldolase B forward 5'-CCAGTTCCCTATG TTCCA-3', reverse 
5'-TTGCTGTGCCTCTTCTAT-3'. Primers of mouse 18s rRNA were purchase from Qiagen 
(Mississauga, ON, Canada). Protein levels were analyzed by Western blotting using 
antibodies as follows: aldolase A (1:5000, Sigma-Aldrich, Oakville, ON, Canada), aldolase B 
(1:500, Epitomics Inc., Burlingame, CA, USA), and β-actin (1:5000, Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA).  
 
5.3.7 Materials  
Sorbinil was a generous gift from Pfizer Inc. (Groton, CT). (E)-2-(4-fluorophenethyl) 
-3-fluoroallylamine (MDL-72974) was a generous gift from Dr. Peter Yu (Department of 
Pharmacology, University of Saskatchewan, Canada). 2-deoxy-D-glucose (2-DG) and diallyl 
disulfide (DADS) were purchased from Sigma-Aldrich, Oakville, ON, Canada.  
 
5.3.8 Statistics 
Data are expressed as mean ± SEM from five independent experiments. Statistical 
analyses were performed using by parametric Student's t-test (two-tailed) or one-way 
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ANOVA followed by posthoc Tukey's test. 
 
5.4 Results 
5.4.1 Insulin enhanced MG formation in adipocytes 
Application of insulin (100 nM) increased basal MG production in 3T3-L1 adipocytes 
(Figure 5-1A). Glucose (25 mM) treatment elevated cellular MG levels, which was further 
augmented by co-treatment with insulin (Figure 5-1A). Glucose analog 2-DG competitively 
inhibits glucose uptake and glycolysis (286). Basal MG levels and the elevated MG levels 
induced by insulin (100 nM), glucose (25 mM) or their combination in adipocytes were 
reduced by application of 2-DG, but not affected by application of sorbinil, a specific aldose 
reductase inhibitor (Figure 5-1A). Incubation of 3T3-L1 adipocytes with fructose (25 mM) or 
fructose plus insulin (100 nM) did not increase MG levels (Figure 5-1B). 
 
5.4.2 Insulin increased glycolysis in adipocytes 
Glucose (25 mM) elevated levels of glucose 6-phosphate (G-6-P, the first metabolite 
of glycolysis) in 3T3-L1 adipocytes. Insulin (100 nM) increased basal and glucose (25 
mM)-induced G-6-P formation (Figure 5-2A). However, insulin (100 nM), glucose (25 mM) 
or their combination had no effect on cellular levels of sorbitol and fructose (Figures 5-2B, 
5-2C).  
We compared the potency of glycolytic metabolites upstream of aldolase A (G-6-P and 
F-1,6-P2) or aldose reductase pathway metabolites upstream of aldolase B (sorbitol, fructose, 
and F-1-P) in generating MG in digitonin-permeabilized adipocytes, since most of these 
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metabolites are cell-impermeable. The amount of MG produced by G-6-P or F-1,6-P2 is 3.2- 
and 6.5-fold above the baseline levels of MG, respectively, and much higher than that 
produced by an equimolar concentration of F-1-P, which was 1.7-fold higher than control. 
Incubation with sorbitol or fructose did not elevate MG levels in digitonin-permeabilized 
adipocytes (Figure 5-2D).  
 
5.4.3 Insulin up-regulated aldolase A gene expression in adipocytes 
Insulin (100 nM) up-regulated mRNA and protein levels of aldolase A in 3T3-L1 
adipocytes, but glucose (25 mM) had no effect on aldolase A gene expression in comparison 
with that from control cells (Figure 5-3A, 5-3B). Application of glucose (25 mM) had no 
effect on insulin (100 nM)-enhanced aldolase A mRNA and protein levels (Figures 5-3A, 
5-3B). However, gene expression of aldolase B (in mRNA and protein levels) was suppressed 
by insulin (100 nM), glucose (25 mM) or their combination in the same adipocytes (Figures 
5-3A, 5-3B).  
 
5.4.4 Knockdown of aldolase A prevented MG formation in adipocytes 
Transfection of 3T3-L1 adipocytes with single siRNA targeting aldolase A or aldolase 
B reduced mRNA levels of aldolase A by 70% and mRNA level of aldolase B by 78%, 
respectively (Figure 5-4A). Since single transfection with aldolase A siRNA elevated mRNA 
levels of aldolase B, we also used adipocytes cells double-transfected with aldolase A and 
aldolase B siRNAs in this study, which had 65% and 70% lower mRNA levels of aldolase A 
and aldolase B, respectively, in comparison to the transfection with control siRNA (Figure 
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5-4A). Basal MG levels were reduced in aldolase A siRNA-transfected cells and, although 
not significantly, in double siRNAs-transfected cells, but not in mock (transfected with only 
transfection agents), or control siRNA or aldolase B siRNA-transfected cells (Figure 5-4B). 
Excess MG production due to incubation with insulin (100 nM), glucose (25 mM) or their 
combination occurred in mock, control siRNA- or aldolase B siRNA-transfected cells, but 
was abolished in aldolase A siRNA- or double siRNAs-transfected cells (Figure 5-4B).  
 
5.4.5 CYP 2E1 and SSAO are not implicated in MG formation in 3T3-L1 adipocytes 
Incubation of 3T3-L1 adipocytes with acetone, acetol, glycerol [converting to DHAP 
during triglycerides degradation (243)], glycine and threonine (glycine and threonine are 
precursors of aminoacetone) at concentration of 25 mM, in the absence or presence of insulin 
(100 nM), did not alter cellular MG levels (Figure 5-5A). Application of DADS or 
MDL-72974, the specific inhibitor of CYP 2E1 and SSAO, respectively, had no effect on 
basal MG formation and excess MG formation induced by insulin (100 nM), glucose (25 mM) 
or their combination in 3T3-L1 adipocytes (Figure 5-5B).   
 
5.5 Discussion 
Our lab previously found that in insulin-insensitive VSMCs, fructose (25 mM) or 
glucose (25 mM) up-regulated aldolase B and promoted MG overproduction (272). In this 
study, we report a different mechanism for MG generation in insulin-sensitive adipocytes 
where fructose (25 mM) has no effect on MG production and glucose (25 mM) only slightly 
increases MG levels. However, insulin (100 nM) up-regulates aldolase A, an enzyme of the 
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glycolytic pathway, and significantly elevates basal and glucose (25 mM)-induced MG 
formation in adipocytes.  
Insulin-insensitive cells (i.e. VSMCs and ECs) and insulin-sensitive cells (i.e. adipose 
and skeletal muscle cells) are traditionally distinguished by their sensitivity to insulin with 
respect to glucose transport. For example, glucose enters cells mainly through an 
insulin-independent GLUT1 in VSMCs while through an insulin-dependent GLUT4 in 
adipocytes (145). MG formation in VSMCs is likely insulin-independent, but here we found 
that insulin plays a crucial role in MG production in adipocytes. In VSMCs, glucose (25 mM) 
raised cellular MG levels by 3-fold, but insulin (100 nM) had no effect on gene expression of 
aldolase A and aldolase B and cellular MG levels when compared with the control group (5 
mM glucose alone) (272). However, in 3T3-L1 adipocytes, we found that insulin (100 nM) 
treatment significantly increased basal MG formation and co-application of insulin and 
glucose (25 mM) significantly augmented glucose-increased MG levels (Figure 5-1).  
Unlike VSMCs, adipocytes less rely on fructose and aldolase B for MG formation. 
Treatment of VSMCs with fructose (25 mM) up-regulated gene expression of GLUT5 and 
aldolase B and increased cellular MG production (272). Exogenous fructose is transported 
into cells through fructose transporter GLUT5 (287). Serum fructose levels are elevated and 
responsible for vascular MG overproduction in metabolic syndrome without hyperglycemia, 
such as obesity and hypertension (272). In addition, fructose-enhanced MG production in 
VSMCs was further augmented by insulin which up-regulated mRNA levels of GLUT5 and 
increased cellular fructose accumulation (272). However, treatment with fructose (25 mM) in 
the absence or presence of insulin (100 nM) did not alter MG generation in 3T3-L1 
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adipocytes (Figure 5-1). Fructose can be produced intracellularly from glucose through the 
aldose reductase pathway. Glucose (25 mM) treatment activated aldose reductase pathway 
and elevated sorbitol and fructose levels in VSMCs and ECs (272, 288), but not in 3T3-L1 
adipocytes (Figure 5-2). Insulin seems not in favor of conversion of fructose from glucose 
(Figure 5-2). Previous studies have provided evidence that insulin did not alter glucose (5 or 
25 mM)-induced sorbitol or fructose formation in erythrocytes, retina and kidney epithelial 
cells (289, 290). Here we also observed that insulin (100 nM) or insulin plus glucose (25 mM) 
did not affect sorbitol and fructose levels in 3T3-L1 adipocytes when compared with control 
cells treated with 5 mM glucose (Figure 5-2). More importantly, insulin (100 nM), glucose 
(25 mM) or their combination suppressed aldolase B expression in adipocytes (Figure 5-3). 
Inhibition of aldose reductase or knockdown of aldolase B did not reduce basal or excess MG 
formation in adipocytes under our tested conditions (Figures 5-1, 5-4).  
Instead, aldolase A and glycolysis becomes the dominant contributor to MG 
generation in adipocytes. Aldolase A cleaves F-1,6-P2 in the glycolytic pathway to yield 
GA3P and DHAP, which are considered as the direct precursors of MG (6, 258, 272). 
Knockdown of aldolase A or application of 2-DG reduced basal MG formation in normal 
glucose-treated 3T3-L1 adipocytes (Figures 5-1, 5-4), suggesting that aldolase A and 
glycolysis mainly account for basal MG formation in adipocytes. MG formation is increased 
with the increase of upstream metabolites (146). In the digitonin-permeabilized adipocytes, 
MG levels were significantly increased by G-6-P and, to a higher extent, by F-1,6-P2 after a 
3-h incubation (Figure 5-2). Glucose (25 mM) elevated G-6-P and MG levels in adipocytes 
although it had no effect on gene expression of aldolase A (Figures 5-1, 5-2 and 5-3). Insulin 
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was found to activate glycolysis in adipocytes (149, 150, 291). Moreover, insulin (100 nM) 
markedly increased aldolase A mRNA and protein levels in the absence or presence of 25 
mM glucose (Figure 5-3), leading to an increased glycolysis and production of MG. Higher 
levels of G-6-P and MG were observed in insulin (100 nM)-treated adipocytes than those in 
glucose (25 mM)-treated adipocytes. In the presence of insulin, glucose (25 mM)-elevated 
G-6-P and MG levels were further increased (Figures 5-1, 5-2). When we blocked glycolysis 
with 2-DG or knocked down aldolase A expression in 3T3-L1 adipocytes, the insulin (100 
nM), glucose (25 mM) or their combination-enhanced MG generation was completely 
prevented (Figures 5-1, 5-4). These data suggest that aldolase A is a key enzyme responsible 
for MG generation in 3T3-L1 adipocytes, and the basal or glucose (25 mM)-elevated MG 
formation was increased by insulin which up-regulated aldolase A.  
Plasma or serum insulin levels are elevated in obesity, hypertension and the early 
stage of type 2 diabetes (272, 283, 284). Our work showing that treatment with insulin 
significantly elevated both basal and glucose (25 mM)-induced MG formation in adipocytes 
is of particular interest since it indicates that MG in adipose tissues may be over-produced by 
hyperinsulinemia in different metabolic syndrome, especially during the early stages when 
significant insulin resistance does not blunt insulin signaling. Thus, the possible 
overproduction of MG in the early stages of hyperinsulinemia may be implicated in the 
development of insulin resistance. Moreover, our recent studies on 3T3-L1 cells demonstrate 
that MG can enhance the mRNA expression of adipogenic markers, such as adiponectin, 
leptin, PPARγ and C/EBPα, and promote adipogenesis of preadipocyte cells (292). Data from 
the present study provides a possible mechanistic link between MG overproduction and 
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obesity development under hyperinsulinemic conditions where the insulin signaling has not 
deteriorated significantly. 
In conclusion, the metabolic pathway for MG formation in insulin-sensitive cells is 
different than that in insulin-insensitive cells. Insulin up-regulates aldolase A and enhances 
MG formation in cultured 3T3-L1 adipocytes. Aldolase A would be a target to reduce excess 
MG generation in insulin-sensitive cells.   
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Figure 5-1 Insulin-enhanced MG formation in 3T3-L1 adipocytes. (A) Insulin (100 
nM)-induced MG formation in adipocytes treated with or without 2-deoxy-D-glucose (2-DG, 
5 mM) or sorbinil (10 μM) for 12 h. (B) MG levels in adipocytes after 12-h incubation with 
fructose alone or plus insulin (100 nM). n= 5 in each group in A and B, 
*
P<0.05, 
**
P<0.01vs. 
5 mM glucose and 
#
P< 0.05,
 ##
P< 0.01 vs. untreated. 
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Figure 5-2 Glucose metabolism in 3T3-L1 adipocytes. (A) Levels of glucose 6-phosphate 
(G-6-P), (B) sorbitol and (C) fructose in adipocytes treated with or without insulin (100 nM) 
for 12 h. 
**
P<0.01 vs. 5 mM glucose and 
##
P< 0.01 vs. glucose alone. (D) Relative MG 
production in digitonin-permeabilized adipocytes after treatment with glucose metabolites, 
G-6-P, fructose 1,6-bisphosphate (F-1,6-P2), sorbitol, fructose, and fructose 1-phosphate 
(F-1-P), at same concentration of 1 mM for 3 h, respectively.  n= 5 in each group in A-D, 
**
P<0.01 vs. control.   
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Figure 5-3 Gene expression of aldolase A and aldolase B in 3T3-L1 adipocytes. (A) 
Real-time PCR and (B) Western blot analysis of aldolase A and aldolase B gene expressions 
in adipocytes treated with or without insulin (100 nM) for 12 h. n= 5 in each group in A and 
B,
 **
P<0.01 vs. 5 mM glucose and 
##
P< 0.01 vs. glucose alone.  
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Figure 5-4 Knockdown of aldolase A prevented MG formation in 3T3-L1 adipocytes. (A) 
mRNA levels of aldolase A or aldolase B, and (B) levels of MG in adipocytes transfected 
with transfection agents (mock) or with control, aldolase A or aldolase B siRNA, or double 
siRNAs. After transfection, cells were grown in medium with or without insulin (100 nM) for 
12 h. n= 4 in each group in A and n=6 in B. 
*
P<0.05, 
**
P<0.01 vs. respective control siRNA.  
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Figure 5-5 Effect of cytochrome P450 2E1 (CYP 2E1) and semicarbazide-sensitive 
amine oxidase (SSAO) on MG formation in 3T3-L1 adipocytes. (A) MG levels in 3T3-L1 
adipocytes treated with acetone, acetol, glycerol, glycine or threonine at the same 
concentration of 25 mM for 12 h. (B) Insulin (100 nM)-induced MG formation in the 
presence or absence of diallyl disulfide (DADS, 100 μM, a CYP 2E1 inhibitor) or 
(E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974, 5 μM, a SSAO inhibitor) for 12 
h. n= 5 for each group in A and B. 
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CHAPTER 6 
 
DISCUSSION AND CONCLUSIONS 
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6.1 General discussion 
Increased MG accumulation in vascular cells has been postulated as an important 
mechanism for diabetic vascular complications (56, 106). Moreover, Dr Wu’s group has 
found that MG was over-produced in VSMCs, aorta and mesenteric arteries of rats with 
hypertension (25, 56, 72, 131). In SHR, MG levels in the plasma and the aorta increase in an 
age-dependent fashion, which is correlated with the increase of blood pressure (131). The 
elevation of MG levels in the aorta is obvious in the 8-week-old SHR when hypertension is 
not yet fully established (131). When SD rats were fed with fructose for 16 weeks, there were 
elevated MG levels in the serum and the aorta with the development of vascular remodeling 
and high blood pressure (25). However, the underlying mechanisms for vascular MG 
overproduction in metabolic syndrome, such as diabetes and hypertension, and the exact role 
of increased MG in the development of vascular complications, were not clear.   
A traditional view regards MG as a product of glycolysis, since the GA3P and DHAP 
generated through glycolysis can spontaneously and non-enzymatically convert to MG (5, 6, 
258). However, this view is challenged by the observation that MG is over-produced in 
VSMCs and the aorta in hypertensive rats which have normal blood glucose levels (25, 56, 
72, 131). This view is also challenged by our finding in chapter 3 that high glucose did not 
change the levels of glucose 6-phosphate and caused a down-regulation of aldolase A gene 
expression in the cultured A-10 cells. Furthermore, we found a down-regulation of aldolase A 
and an overproduction of MG in the aorta of diabetic rats.  
Interestingly, we observed that levels of serum and aortic fructose and MG and mRNA 
levels of aortic aldolase B were increased in different rat models of metabolic syndrome, 
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including fructose-fed SD rats, SHR, obese non-diabetic Zucker rats and diabetic Zucker rats. 
However, the mRNA levels of aortic aldolase A were unchanged or even down-regulated in 
these rat models. Fructose increased MG generation in VSMCs (66). Chronically feeding 
fructose increased serum and aortic MG levels and elevated blood pressure in SD rats, but the 
blood glucose remained within the normal range (25, 147). In this project, we found that 
fructose (25 mM) had no effect on aldolase A expression, but up-regulated aldolase B 
expression in VSMCs. Knockdown of aldolase B completely prevented fructose (25 
mM)-elevated MG generation in A-10 cells. These data suggest that up-regulation of aldolase 
B by increased fructose is a reason for MG over-production in the aorta of hypertensive or 
obese rats with normoglycemia.  
We found that insulin up-regulated GLUT5, leading to increased fructose uptake and 
MG generation in VSMCs. We also found that blood insulin levels and aortic GLUT5 mRNA 
levels are elevated in hypertensive or obese rats. However, in the hypertension or obesity, 
vascular tissues are insulin resistant (298, 299). Whether the high blood insulin contributes to 
the up-regulation of GLUT5 and overproduction of MG in aorta of fructose-fed SD rats, SHR, 
or obese Zucker rats requires further investigation. It is possible that in the early stages when 
hyperinsulinemia starts developing, the insulin signaling may not have deteriorated enough to 
blunt the response to hyperinsulinemia, in which case more MG can be produced.   
It is well known that high glucose saturates hexokinase (the first enzyme in glycolysis) 
but elevates flux through the polyol pathway and produces fructose (153, 154). Does fructose 
and aldolase B contribute to vascular MG overproduction in diabetic rats? Here we found that 
high glucose activated the polyol pathway, increased fructose production and up-regulated 
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gene expression of aldolase B in the cultured A-10 cells. More importantly, the elevated MG 
generation produced by high glucose was prevented by blockage of polyol pathway or by 
knockdown of aldolase B, but only partially reduced by knockdown of aldolase A in VSMCs. 
The results suggest that the increased fructose production from glucose and up-regulated 
aldolase B mainly account for hyperglycemia-induced MG overproduction in vascular cells 
in diabetes. Our work identifies a common pathway, fructose-aldolase B pathway, for 
vascular MG generation in different rat models of metabolic syndrome with or without 
hyperglycemia. However, the basal MG levels in A-10 cells treated with 5 mM glucose was 
not reduced by knockdown of aldolase B but reduced by knockdown of aldolase A, 
suggesting that aldolase A plays a role for the basal MG formation in vascular cells under 
physiological conditions.  
Endothelial dysfunction occurs at the early stage of many pathological conditions 
such as diabetes mellitus, hypertension and atherosclerosis, and is a major risk factor of 
cardiovascular complications in the metabolic syndrome (136). Increased MG accumulation 
is considered as an important molecular mechanism linking diabetes to endothelial damage 
(36, 70, 87). However, whether knockdown of aldolase B can prevent high glucose-induced 
MG overproduction and related endothelial cell dysfunction are largely unsettled. Our study 
in chapter 4 identified aldolase B as the major enzyme responsible for high glucose (25 
mM)-increased MG overproduction in endothelial cells. We found that knockdown of 
aldolase B not only prevented high glucose-elevated MG overproduction but also prevented 
high glucose-induced activation of multiple metabolic and signaling pathways, including 
AGEs accumulation, oxidative stress, O-GlcNAc modification, membrane protein kinase C 
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activity and nuclear translocation of NF-κB. Our data indicate that normalizing MG 
generation by aldolase B knockdown prevented high glucose-induced cellular dysfunction in 
endothelial cells. This conclusion was supported by our findings that the application of 
aminoguanidine (a non-specific MG scavenger) or alagebrium (an AGEs breaker), to a lesser 
extent, attenuated these metabolic and signaling alterations induced by high glucose. On the 
other hand, we found that MG (100 µM) directly increased AGEs formation and oxidative 
stress, and activated the above metabolic and signaling pathways in endothelial cells to nearly 
the same extent as did high glucose (25 mM). These results indicate an exact role of MG in 
the toxicity of high glucose as an upstream activator for other metabolic and signaling 
pathways. Aldolase B is likely a promising and novel target in preventing glucose-induced 
overproduction of MG and related endothelial dysfunction in diabetes.   
The last part of my PhD program was to study the MG formation in insulin-sensitive 
adipose cells. A recent study in our lab demonstrated that incubation of 3T3-L1 adipocytes 
with MG impaired insulin signaling pathways and insulin-stimulated glucose uptake (147). 
However, whether MG is over-produced in adipocytes in the metabolic syndrome and the 
underlying mechanism are unknown. Unlike those in insulin-insensitive VSMCs, glucose 
transport and metabolism in adipose cells are insulin-dependent (291). Insulin can stimulate 
glucose uptake through insulin-responsive GLUT4 (148) and enhance glycolysis in 
adipocytes (149, 150). It was reported that hyperinsulinemia associated with obesity 
significantly increased glucose uptake and glycolysis in adipose tissues (293). Our studies in 
vitro showed that the application of insulin (100 nM), high glucose (25 mM) or their 
combination up-regulated aldolase A expression and increased G-6-P and MG levels in 
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cultured 3T3-L1 adipocytes when compared with the control cells treated with 5 mM glucose. 
Knockdown of aldolase A expression or blockage of glycolysis decreased the basal level of 
MG and prevented MG overproduction induced by insulin, high glucose or their combination. 
In contrast, insulin (100 nM), high glucose (25 mM), or their combination had no effect on 
cellular levels of sorbitol and fructose, in comparison with that from the control group. 
Furthermore, insulin (100 nM), high glucose (25 mM), and insulin plus high glucose reduced 
the mRNA and protein of aldolase B to a similar lower level. Knockdown of aldolase B 
expression or blockage of the polyol pathway did not reduce MG overproduction induced by 
insulin, high glucose or their combination in 3T3-L1 adipocytes. This work indicates that 
insulin enhances glycolysis and aldolase A expression, leading to excess MG formation in 
adipocytes.  
SSAO-catalyzed deamination of aminoacetone and CYP 2E1-catalyzed catabolism of 
acetone are considered as the important sources for cellular MG generation (10). The role of 
SSAO in MG overproduction received much attention due to the significantly raised plasma 
SSAO activity in diabetes and hypertension (131, 294). Acetone is considered as a potential 
source for MG overproduction since the plasma level of acetone is significantly increased in 
patients with diabetes, which can be up to 8.9 mM in diabetic ketoacidosis (295). However, in 
this project, we found that even incubation with aminoacetone or acetone at a concentration 
of 25 mM for 12 h did not alter MG levels in VSMCs or adipose cells. Application of the 
specific inhibitor of CYP 2E1 or SSAO unchanged either basal MG formation or excess MG 
formation induced by fructose, glucose and/or insulin in cultured VSMCs, endothelial cells 
and adipose cells, suggesting that CYP 2E1 and SSAO were not implicated with either 
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vascular or adipose MG formation. However, since our studies have been performed in 
cultured VSMCs, endothelial cells and adipose cells, we cannot rule out the role of CYP2E1 
and SSAO in MG production in vivo in different disease conditions. 
 
6.2 Conclusions 
Fructose up-regulated aldolase B and enhanced MG generation in VSMCs. Levels of 
serum and aortic fructose were increased in the obese or hypertensive rats, leading to 
up-regulation of aldolase B and overproduction of MG in the aorta. High glucose activated 
the polyol pathway and increased fructose and MG production in VSMCs, endothelial cells, 
and in the aorta of diabetic rats. Knockdown of aldolase B completely prevented high 
fructose or glucose-induced MG overproduction in VSMCs and high glucose-induced MG 
overproduction in endothelial cells. Thus, local aortic smooth muscle MG production may be 
contributing to the development of increased vascular contractility, hypertension and 
atherosclerosis.    
MG is an upstream mediator for high glucose-induced biochemical abnormalities and 
endothelial cell dysfunction. Knockdown of aldolase B prevented high glucose-increased 
AGEs formation, oxidative stress, and activation of the PKC, O-GlcNAc, and NFκB 
pathways. Endothelial overproduction of MG can contribute to endothelial dysfunction, and 
the development of reduced endothelium-dependent relaxation, increased vascular 
contractility, prothrombotic tendency and hypertension and atherosclerosis. In the capillary 
endothelial cells, such as those in the adipose tissue, it can also contribute to abnormalities in 
the function of lipoprotein lipase, triglyceride/fatty acid exchange and dyslipidemia. Thus, 
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more work needs to be done to substantiate these possibilities.    
Insulin did not change the glucose metabolism through the polyol pathway and 
down-regulated aldolase B, but up-regulated aldolase A and increased MG generation in 
insulin-sensitive adipose cells. Blockage of glycolysis or knockdown of aldolase A prevented 
the excess MG generation induced by high insulin in adipose cells. An overproduction of MG 
in the adipose cells may be lipogenic leading to adipose tissue fat accumulation and 
contributing to central obesity in the metabolic syndrome. 
The net in vivo contribution of elevated MG production in several different cell types 
may thus contribute to the different abnormalities that together make up the metabolic 
syndrome. In this regard we need to study MG production in other cell types such the 
hepatocytes, the kidney cells, skeletal muscle cells and the brain cells.   
 
6.3 Significance of the study 
The significance of the studies from my Ph.D. program is the identification of two key 
enzymes, aldolase A and aldolase B, that contribute to MG overproduction in different cell 
types. Inhibitors targeting these enzymes can be designed and investigated leading to the 
development of potential therapeutic agents. Thus, we have elucidated the important role of 
fructose-AldoB pathway in vascular MG overproduction and vascular function in different 
subtypes of metabolic syndrome. Increased MG accumulation in blood vessels has been 
implicated in the development of vascular complications in metabolic syndrome. We, for the 
first time, identify fructose-AldoB pathway as a common pathway for vascular MG 
overproduction in different metabolic syndrome. Aldolase B is a key enzyme for MG 
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overproduction in insulin-insensitive vascular smooth muscle cells and endothelial cells. 
Specifically targeting the aldolase B might represent a new avenue for the prevention and 
treatment of hypertension and vascular complications of diabetes. More importantly, we 
found that aldolase B knockdown has a greater inhibitory effect on high glucose-induced 
endothelial abnormalities than application of aminoguanidine and alagebrium (the most 
widely used MG scavenger and AGEs breaker, respectively).  
We found, for the first time, that insulin can increase MG generation in 
insulin-sensitive adipose cells. Levels of blood insulin are increased in the hypertension and 
obesity (272, 283, 284). Our work suggests a linkage between hyperinsulinemia, MG, and 
development of insulin resistance and obesity with the understanding that the relation 
between hyperinsulinemia, insulin signaling sensitivity and defects, and MG production in 
the adipose tissue needs to be established in the pre-, early and late stages of obesity in vivo. 
However, we found it is aldolase A, but not aldolase B, that is up-regulated by high insulin 
and mainly responsible for MG overproduction in adipose cells, indicating aldolase A as a 
target to prevent adipose MG overproduction in metabolic syndrome.  
 
6.4 Limitations of the study 
Increased serum and urinary fructose concentrations were reported in patients with 
diabetes (162). Hyperglycemia-induced activation of the polyol pathway has been postulated 
to be an important mechanism, since the increases in gene expression and activities of aldose 
reductase and sorbitol dehydrogenase, and increases in cellular levels of the polyol pathway 
metabolites, sorbitol and fructose, have been widely observed in different tissues of diabetic 
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animals (242, 296, 297). Our studies in chapter 3 report that the serum fructose levels are 
elevated in obese or hypertensive rats and, to a higher extent, in diabetic rats. However, no 
study is available to clarify the reason for the fructose elevation in metabolic syndrome 
without hyperglycemia and the reason for the higher increase of serum fructose in diabetes 
than hypertension and obesity.   
In Chapter 3, we incubated cultured VSMCs with glucose at concentration of 25 mM 
to mimic the hyperglycemia of diabetics and, for comparative purposes, we have to use the 
same concentration of 25 mM for fructose. Inevitably, this concentration of fructose used is 
much higher than the pathological serum levels of fructose (1-2 mM). However, we can argue 
that chronic elevations of serum fructose even in the 1-2 mM range over several years are 
likely to cause progressive cumulative metabolic changes and damage to the involved cells. 
The use of higher concentrations in acute studies ranging from 3 h to 5 days, is universally 
practiced and accepted and helps to reveal possible long-term consequences of lower 
concentrations encountered in vivo. From the current studies in Chapter 3, it is not clear 
whether the elevated serum MG is also caused by a release of excess MG from VSMCs 
and/or from endothelial cells. MG can cross the cell membrane to a limited extent and in one 
study about 10% of MG synthesized in cells was released into the surrounding environment 
(34). Moreover, increased MG accumulation has been also reported in the retina and the 
kidney (87), which contain several different types of cells. The contribution of MG formed in 
vascular cells to the MG accumulation in blood and organs need to be clarified in vivo in 
mice with cell-specific knockout of aldolase B.  
In Chapter 4, we identify MG as a mediator for high glucose-induced changes in 
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different biochemical pathways, but the underlying mechanism of how MG activates these 
pathways were not addressed. MG increased oxidative stress through impairing 
mitochondrial function, up-regulating NADPH oxidase, and reducing cellular antioxidant 
defences (66, 70). The role of MG in the increase of O-GlcNAc modification, activation of 
PKC and NF-κB, and in their related deleterious actions requires extensive further studies. 
Moreover, generally speaking, endothelial dysfunction includes the impaired 
endothelium-dependent relaxation, vascular remodeling and other pathological changes in 
blood vessels. The relationship between MG and endothelial dysfunction needs further 
investigation in isolated blood vessels or in vivo in animals.  
The last question for our studies is how insulin and carbohydrates regulate gene 
expression of aldolase A and aldolase B. Whether insulin or carbohydrates affect the mRNA 
and protein stability of aldolase A or aldolase B, or regulate the post-transcription of these 
enzymes is totally unknown. It is quite likely that insulin, glucose and fructose may be 
delaying or attenuating mRNA or protein degradation of aldolase A or aldolase B. We also 
observed that high glucose up-regulated aldolase B in VSMCs but down-regulated aldolase B 
in adipose cells. Insulin had no effect on aldolase A in VSMCs but up-regulated aldolase A in 
adipose cells. The cell-specific manner of gene regulation may be caused by the cell-specific 
distribution of nuclear transcription factors. For example, hepatocyte nuclear factor 1 
(HNF-1), an important transactivator of the aldolase B gene promoter, is highly expressed in 
the liver and the kidney, but not in the spleen and the lungs (300).    
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